<Bundle xmlns="http://hl7.org/fhir"><id value="33cc17dc-2fae-4b52-a9c1-3198c08e84ad" /><identifier><system value="http://ema.europa.eu/fhir/epiGuid" /><value value="33cc17dc-2fae-4b52-a9c1-3198c08e84ad" /></identifier><type value="collection" /><timestamp value="2024-12-04T17:54:32.9550059+01:00" /><entry><fullUrl value="11590e4f-94a4-4adc-a0c2-2945b9337330" /><resource><List><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) master document list</div></text><identifier><system value="http://ema.europa.eu/fhir/epiId" /><value value="EPI/24/129" /></identifier><status value="current" /><mode value="working" /><title value="all sections Spanish document" /><code><coding><system value="http://ema.europa.eu/fhir/documentType" /><code value="00001" /><display value="epiMasterList" /></coding></code><subject><reference value="subjectReference" /></subject><entry><item><reference value="referenceToDocument" /><display value="Ficha técnica o resumen de las características del producto" /></item></entry><entry><item><reference value="referenceToDocument" /><display value="Prospecto" /></item></entry></List></resource></entry><entry><fullUrl value="40dd7577-855a-4a1a-b7aa-642888bd91be" /><resource><Bundle><id value="40dd7577-855a-4a1a-b7aa-642888bd91be" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="40dd7577-855a-4a1a-b7aa-642888bd91be" /></identifier><type value="document" /><timestamp value="2024-12-04T17:54:32.9524879+01:00" /><entry><fullUrl value="40dd7577-855a-4a1a-b7aa-642888bd91be" /><resource><Composition><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="100000155532" /><display value="Ficha técnica o resumen de las características del producto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2024-12-04" /><author><reference value="systemUser" /></author><title value="Ficha técnica o resumen de las características del producto" /><section><title value="Ficha técnica o resumen de las características del producto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="200000029791" /><display value="Ficha técnica o resumen de las características del producto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="646ec488-dbdf-4229-8aae-733308691706"><title value="1. Nombre del medicamento" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029792" /><display value="Nombre del medicamento" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos recubiertos con película</span></p></div></text></section><section id="4e8fe847-18e5-4589-a0ff-3fdbbe7625d5"><title value="2. Composición cualitativa y cuantitativa" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029793" /><display value="Composición cualitativa y cuantitativa" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Cada comprimido recubierto con película contiene 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de raltegravir (potásico).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Excipiente(s) con efecto conocido</span></span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Cada comprimido de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">contiene 5,72</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de lactosa (como monohidrato).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Para consultar la lista completa de excipientes, ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6.1.</span></p></div></text></section><section id="79a84838-bcda-44d0-92c9-87c8248c6e79"><title value="3. Forma farmacéutica" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029797" /><display value="Forma farmacéutica" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Comprimido recubierto con película.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Comprimido de color amarillo, que presenta forma ovalada, con unas dimensiones de 19,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mm x 9,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mm x 6,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mm, con el logo corporativo MSD y la inscripción “242” grabada en una de las caras y la otra cara lisa.</span></p></div></text></section><section id="51673fc5-a9cf-4a3b-a17a-025bd52860d0"><title value="4. Datos clínicos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029798" /><display value="Datos clínicos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="049f6e15-1e4a-46c1-8ef3-dfca5eafc998"><title value="4.1. Indicaciones terapéuticas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029799" /><display value="Indicaciones terapéuticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos recubiertos con película está indicado en combinación con otros fármacos antirretrovirales para el tratamiento de la infección por el virus de la inmunodeficiencia humana (VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1) en adultos y en pacientes pediátricos con un peso de al menos 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2, 4.4, 5.1 y 5.2).</span></p></div></text></section><section id="c18ef870-1aee-41bf-a059-b8ca4d0000b3"><title value="4.2. Posología y forma de administración" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029800" /><display value="Posología y forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">El tratamiento debe instaurarlo un médico con experiencia en el tratamiento de la infección por el VIH.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text><section id="368e23bd-2787-48e1-998c-f1cdd0c0a1cb"><title value="4.2.1. Posología" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029801" /><display value="Posología" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS se debe usar en combinación con otros antirretrovirales (ARTs) activos (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4 y 5.1).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Adultos y población pediátrica</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En adultos y pacientes pediátricos (con un peso de al menos 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg), la dosis recomendada es de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (dos comprimidos de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg)</span><span style="font-family:Times New Roman; font-size:11pt">una vez al día para pacientes no tratados previamente o para pacientes virológicamente suprimidos en tratamiento inicial con</span><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Formulaciones y concentraciones adicionales disponibles:</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS también está disponible en comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg para ser administrado dos veces al día en adultos o niños y adolescentes de al menos 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg infectados por el VIH. No se debe utilizar el comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg para administrar la pauta posológica de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día (consultar la ficha técnica del comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS también está disponible en una formulación en comprimido masticable y en formulación en granulado para suspensión oral. Para obtener más información sobre la posología, consultar las fichas técnicas del comprimido masticable y del granulado para suspensión oral.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No se ha establecido la seguridad y la eficacia de raltegravir en recién nacidos prematuros (&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">37</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de gestación) y de bajo peso al nacer (&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">g). No se dispone de datos en esta población y no se pueden hacer recomendaciones posológicas.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">La dosis máxima para el comprimido masticable es de 300</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día. Debido a que las formulaciones tienen perfiles farmacocinéticos diferentes, no se deben sustituir ni los comprimidos masticables ni el granulado para suspensión oral por el comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg o por el comprimido de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2). Los comprimidos masticables y el granulado para suspensión oral no han sido estudiados en adolescentes (de 12 a 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años) o adultos infectados por el VIH.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes de edad avanzada</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Existe poca información sobre el uso de raltegravir en pacientes de edad avanzada (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2). Por consiguiente, ISENTRESS se debe usar con precaución en esta población.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia renal</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis en los pacientes con insuficiencia renal (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia hepática</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis en los pacientes que presentan insuficiencia hepática de leve a moderada. No se ha establecido la seguridad y eficacia de raltegravir en pacientes con trastornos hepáticos graves subyacentes. Por consiguiente, ISENTRESS se debe usar con precaución en pacientes con insuficiencia hepática grave (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4 y 5.2).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">La formulación de ISENTRESS 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos recubiertos con película no se debe utilizar en niños con un peso inferior a 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="b9c31e0b-1db4-48c8-9755-8e5a98ba24ff"><title value="4.2.2. Forma de administración" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029803" /><display value="Forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Vía oral.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">ISENTRESS 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos se puede administrar con o sin comida como una dosis de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg administrados una vez al día.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se deben masticar, machacar o partir los comprimidos, debido a que se anticiparían cambios en el perfil farmacocinético.</span></p></div></text></section></section><section id="358fce0c-41f4-4d29-8ed0-4e40c2c2c1c1"><title value="4.3. Contraindicaciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029805" /><display value="Contraindicaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Hipersensibilidad al principio activo o a alguno de los excipientes incluidos en la sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6.1.</span></p></div></text></section><section id="c9fe1f83-7fad-41d4-879b-82db0d03eff0"><title value="4.4. Advertencias y precauciones especiales de empleo" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029806" /><display value="Advertencias y precauciones especiales de empleo" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Generales</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se debe advertir a los pacientes que el tratamiento antirretroviral actual no cura la infección por el VIH y que no se ha demostrado que evite la transmisión del VIH a otras personas a través del contacto sanguíneo.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir tiene una barrera genética a la resistencia relativamente baja. Por consiguiente, siempre que sea posible, raltegravir se debe administrar con otros dos ARTs activos para reducir al mínimo el potencial de fracaso virológico y el desarrollo de resistencia (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes no tratados previamente, los datos del estudio clínico sobre el uso de raltegravir están limitados al uso en combinación con dos inhibidores nucleótidos de la transcriptasa inversa (INTI) (emtricitabina y tenofovir disoproxilo fumarato).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-indent:-28.35pt; page-break-after:avoid; padding-left:28.35pt" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Depresión</span></span></p><p style="margin:0pt; text-indent:-28.35pt; page-break-after:avoid; padding-left:28.35pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se ha notificado depresión, incluyendo ideas y conductas suicidas, especialmente en pacientes con antecedentes preexistentes de depresión o enfermedad mental. Se debe tener precaución en pacientes con antecedentes preexistentes de depresión o enfermedad mental.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia hepática</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha establecido la seguridad y eficacia de raltegravir en pacientes con trastornos hepáticos graves subyacentes. Por consiguiente, raltegravir se debe usar con precaución en pacientes con insuficiencia hepática grave (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2 y 5.2).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes con disfunción hepática preexistente, incluida la hepatitis crónica, tienen una mayor frecuencia de anomalías de la función hepática durante el tratamiento antirretroviral de combinación y se deben controlar de acuerdo con la práctica convencional. Si existe evidencia de empeoramiento de la enfermedad hepática en dichos pacientes, se debe considerar la interrupción o la suspensión del tratamiento.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes con hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B o C crónica y tratados con tratamiento antirretroviral de combinación presentan un mayor riesgo de reacciones adversas hepáticas graves y potencialmente mortales.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Osteonecrosis</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Aunque se considera que la etiología es multifactorial (incluido el uso de corticosteroides, el consumo de alcohol, la inmunosupresión grave, el aumento del índice de masa corporal), se han notificado casos de osteonecrosis, especialmente en pacientes con infección por el VIH avanzada y/o exposición a largo plazo al tratamiento antirretroviral de combinación. Se debe advertir a los pacientes que acudan al médico si desarrollan molestias y dolor articular, rigidez articular o dificultad de movimiento.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Síndrome de reconstitución inmune</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En los pacientes infectados por el VIH con inmunodeficiencia grave en el momento de la instauración del tratamiento antirretroviral de combinación (TARC) se puede producir una reacción inflamatoria a patógenos oportunistas asintomáticos o residuales, la cual puede causar trastornos clínicos graves o agravar los síntomas. Habitualmente, dichas reacciones se observan en las primeras semanas o meses después del inicio del TARC. Algunos ejemplos relevantes son retinitis por citomegalovirus, infecciones por micobacterias generalizadas y/o focales y neumonía causada por</span><em><span style="font-family:Times New Roman; font-size:11pt;">Pneumocystis jiroveci</span></em><span style="font-family:Times New Roman; font-size:11pt">(antes conocido como</span><em><span style="font-family:Times New Roman; font-size:11pt;">Pneumocystis carinii</span></em><span style="font-family:Times New Roman; font-size:11pt">). Se deben evaluar todos los síntomas inflamatorios y se debe instaurar un tratamiento cuando sea necesario</span><em><span style="font-family:Times New Roman; font-size:11pt;">.</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">También se ha notificado la aparición de trastornos autoinmunitarios (como por ejemplo la enfermedad de Graves</span><span style="font-family:Times New Roman; font-size:11pt">y la hepatitis autoinmune</span><span style="font-family:Times New Roman; font-size:11pt">) durante la reconstitución inmune; sin embargo, el tiempo notificado hasta su aparición es más variable y estos acontecimientos pueden suceder muchos meses después del inicio del tratamiento.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Atazanavir</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La administración simultánea de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de raltegravir una vez al día con atazanavir dio lugar a un aumento de los niveles plasmáticos de raltegravir; por lo tanto, no se recomienda su administración simultánea (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tipranavir/ritonavir</span></span></p><p style="margin:0pt; text-align:justify; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La administración simultánea de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de raltegravir una vez al día con tipranavir/ritonavir podría dar lugar a una disminución de los niveles plasmáticos mínimos de raltegravir; por lo tanto, no se recomienda su administración simultánea (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Antiácidos</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La administración simultánea de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día con antiácidos que contienen carbonato de calcio y aluminio/magnesio dio lugar a una disminución de los niveles plasmáticos de raltegravir; por lo tanto, no se recomienda su administración simultánea (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.5).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Inductores potentes de las enzimas que metabolizan medicamentos</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los inductores potentes de las enzimas que metabolizan medicamentos (p. ej., rifampicina) no han sido estudiados con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día, pero podrían producir una disminución de los niveles plasmáticos mínimos de raltegravir; por lo tanto, no se recomienda la administración simultánea con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Miopatía y rabdomiólisis</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado casos de miopatía y rabdomiólisis. Utilizar con precaución en pacientes que hayan tenido en el pasado miopatía o rabdomiólisis o que tengan cualquier factor desencadenante, incluyendo otros medicamentos asociados a estas enfermedades (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Reacciones cutáneas graves y de hipersensibilidad</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado reacciones cutáneas graves, potencialmente mortales y mortales en pacientes tratados con raltegravir, en la mayoría de los casos simultáneamente con otros medicamentos asociados con estas reacciones. Estas incluyen casos de síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. También se han notificado reacciones de hipersensibilidad caracterizadas por erupción, síntomas generales y, a veces, disfunción de órganos, incluyendo fallo hepático. Interrumpa inmediatamente raltegravir y otros agentes sospechosos si aparecen signos o síntomas de reacciones cutáneas graves o reacciones de hipersensibilidad (incluyendo, aunque no se limita a, erupción grave o erupción acompañada de fiebre, malestar general, fatiga, dolores musculares o articulares, ampollas, lesiones orales, conjuntivitis, edema facial, hepatitis, eosinofilia, angioedema). El estado clínico, incluyendo transaminasas hepáticas, se debe controlar y se debe iniciar un tratamiento apropiado. El retraso en la interrupción del tratamiento con raltegravir u otros agentes sospechosos, después de la aparición de erupción grave, puede desencadenar una reacción potencialmente mortal.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Erupción</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La aparición de erupción se produjo con más frecuencia en pacientes tratados previamente con regímenes que contenían raltegravir y darunavir en comparación con los pacientes que recibían raltegravir sin darunavir o darunavir sin raltegravir (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Lactosa</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene lactosa. Los pacientes con intolerancia hereditaria a galactosa, deficiencia total de lactasa o problemas de absorción de glucosa o galactosa no deben tomar este medicamento.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Sodio</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene menos de 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mmol de sodio (23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) por comprimido; esto es, esencialmente “exento de sodio”. </span></p></div></text></section><section id="f87404dd-0f1b-4fde-b979-85286f902656"><title value="4.5. Interacción con otros medicamentos y otras formas de interacción" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029809" /><display value="Interacción con otros medicamentos y otras formas de interacción" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">In vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">, raltegravir es un inhibidor débil del transportador de aniones orgánicos (OAT)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 (IC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">de 109</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µM) y OAT3 (IC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">de 18,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">µM). Se recomienda tener precaución cuando se administre de forma conjunta raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día con sustratos sensibles de OAT1 y/o OAT3.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los estudios</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">indicaron que raltegravir no es un sustrato de las enzimas del citocromo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">P450</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(CYP), no inhibe las enzimas CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 o CYP3A, no inhibe las UDP</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">glucuronosiltransferasas (UGTs) 1A1 y 2B7, no induce la CYP3A4 y no es un inhibidor de la glucoproteína</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">P (gp</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">P), de la proteína de resistencia al cáncer de mama (BCRP), de los polipéptidos transportadores de aniones orgánicos (OATP) 1B1, OATP1B3, de los transportadores de cationes orgánicos (OCT)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y OCT2 o de las proteínas de extrusión de multifármacos y tóxicos (MATE)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y MATE2-K. Según estos datos, no cabe esperar que raltegravir afecte a la farmacocinética de los medicamentos que son sustratos de estas enzimas o transportadores.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Según los resultados de estudios</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">e</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vivo</span></em><span style="font-family:Times New Roman; font-size:11pt">, raltegravir se elimina principalmente metabolizándose por glucuronidación por la vía mediada por la UGT1A1.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se observó una considerable variabilidad interindividual e intraindividual en la farmacocinética de raltegravir.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Efecto de raltegravir sobre la farmacocinética de otros medicamentos</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En estudios de interacciones farmacológicas realizados con raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, raltegravir no tuvo un efecto clínicamente significativo sobre la farmacocinética de etravirina, maraviroc, tenofovir disoproxilo fumarato, anticonceptivos hormonales, metadona, midazolam o boceprevir. Estos resultados se pueden extrapolar a raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y no es necesario ajustar la dosis de estos medicamentos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En algunos estudios, la administración simultánea de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos dos veces al día con darunavir produjo un descenso moderado, pero clínicamente insignificante, de las concentraciones plasmáticas de darunavir. Basado en la magnitud del efecto observado con raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos dos veces al día, se prevé que, probablemente, el efecto de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día sobre las concentraciones plasmáticas de darunavir no sea clínicamente significativo.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Efecto de otros medicamentos sobre la farmacocinética de raltegravir</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Inductores de las enzimas que metabolizan medicamentos</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se desconoce el efecto de los medicamentos que son inductores potentes de la UGT1A1, como la rifampicina, sobre</span><span style="font-family:Times New Roman; font-size:11pt">raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día, pero es probable que su administración simultánea reduzca los niveles mínimos de</span><span style="font-family:Times New Roman; font-size:11pt">raltegravir basado en la reducción de las concentraciones mínimas observadas con raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día; por lo tanto, no se recomienda la administración simultánea con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día. Se desconoce el efecto que tienen otros inductores potentes de las enzimas que metabolizan medicamentos, como fenitoína y fenobarbital sobre la UGT1A1; por lo tanto, no se recomienda la administración simultánea con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día. En los estudios de interacciones farmacológicas, efavirenz no presentó un efecto clínicamente significativo sobre la farmacocinética de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día; por lo tanto, otros inductores menos potentes (por ejemplo, efavirenz, nevirapina, rifabutina, glucocorticoides, hierba de San Juan, pioglitazona) se pueden utilizar con la dosis recomendada de raltegravir.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores de la UGT1A1</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La administración simultánea de atazanavir con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día aumentó de forma significativa los niveles plasmáticos de raltegravir; por lo tanto, no se recomienda la administración simultánea de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y atazanavir.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Antiácidos</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Probablemente, la administración simultánea de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día con antiácidos que contienen aluminio/magnesio y carbonato de calcio dé lugar a reducciones clínicamente significativas de los niveles plasmáticos mínimos de raltegravir. Basado en estos hallazgos, no se recomienda la administración simultánea de antiácidos que contienen aluminio/magnesio y carbonato de calcio con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Medicamentos que aumentan el pH gástrico</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el análisis farmacocinético poblacional del estudio ONCEMRK (protocolo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">292) se observó que la administración simultánea de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día con inhibidores de la bomba de protones (IBP) o antagonistas H2 no provocó variaciones estadísticamente significativas en la farmacocinética de raltegravir. Se obtuvieron resultados de eficacia y seguridad comparables en ausencia o presencia de estos medicamentos modificadores del pH gástrico. Basado en estos datos, los IBP y los antagonistas H2 pueden administrarse simultáneamente con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Consideraciones adicionales</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se ha realizado ningún estudio para evaluar las interacciones farmacológicas de ritonavir, tipranavir/ritonavir, boceprevir o etravirina con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (2 x 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) una vez al día. Aunque la magnitud del cambio en la exposición a raltegravir de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día producido por ritonavir, boceprevir o etravirina era pequeña, el efecto de tipranavir/ritonavir fue mayor (GMR de la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">mín</span><span style="font-family:Times New Roman; font-size:11pt">=0,45, GMR del AUC=0,76). No se recomienda la administración simultánea de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y tipranavir/ritonavir.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Estudios previos de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día señalaron que la administración simultánea de tenofovir disoproxilo fumarato (un componente de emtricitabina/tenofovir disoproxilo fumarato) aumentó la exposición a raltegravir. Se determinó que emtricitabina/tenofovir disoproxilo fumarato aumentaba la biodisponibilidad de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día un 12%, aunque su efecto no es clínicamente significativo. Por lo tanto, se permite la administración simultánea de emtricitabina/tenofovir disoproxilo fumarato y raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día.</span></p><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Todos los estudios de interacción fueron realizados en adultos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han realizado estudios exhaustivos de interacciones farmacológicas con raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y un número limitado de estudios de interacciones farmacológicas con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">En la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 se muestran todos los datos de los estudios de interacciones disponibles junto con las recomendaciones respecto a la administración simultánea.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Datos de interacción farmacocinética</span></strong></p><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Medicamentos por área terapéutica</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Interacción</span></strong></p><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">(mecanismo, si se conoce)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Recomendaciones relativas a la administración simultánea</span></strong></p></td></tr></thead><tbody><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANTIRRETROVIRALES</span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores de la proteasa (IP)</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">atazanavir/ritonavir</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑41</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑77</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(inhibición de la UGT1A1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg</span><span style="font-family:Times New Roman; font-size:11pt">dos veces al día).</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.9pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">atazanavir</span></strong></p><p style="margin:0pt 0pt 0pt 10.9pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">67</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(inhibición de la UGT1A1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No se recomienda la administración simultánea de raltegravir (1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día).</span></p></td></tr><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">tipranavir/ritonavir</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓55</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(inducción de la UGT1A1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día).</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Extrapolado del estudio de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No se recomienda la adm</span><span style="font-family:Times New Roman; font-size:11pt">inistración simultánea de raltegravir (1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día).</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores no nucleósidos de la transcriptasa inversa (INNTI)</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">efavirenz</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓21</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(i</span><span style="font-family:Times New Roman; font-size:11pt">nducción de la UGT1A1)</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día).</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.9pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">efavirenz</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">14% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">9% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(inducción de la UGT1A1)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">etravirina</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓34</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(inducción de UGT1A1)</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de etravirina</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de etravirina</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de etravirina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día</span><span style="font-family:Times New Roman; font-size:11pt">y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de etravirina.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores nucleósidos/nucleótidos de la transcriptasa inversa (INTI)</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">tenofovir disoproxilo fumarato</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑49</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑64</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de r</span><span style="font-family:Times New Roman; font-size:11pt">altegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(mecanismo de interacción desconocido)</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de tenofovir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de tenofovir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de tenofovir</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de tenofovir diso</span><span style="font-family:Times New Roman; font-size:11pt">proxilo fumarato.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.9pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">emtricitabina y tenofovir disoproxilo fumarato</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">x</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) una vez al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">El análisis farmacocinético poblacional mostró que el efecto de emtricitabina/tenofovir disoproxilo fumarato sobre la farmacocinética de raltegravir era mínimo (aumento del 12% en la biodisponibilidad relativa), y no resultó ni estadística ni clínicamente significativo.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(Mecanismo de interacción desconocido)</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores del CCR5</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">maraviroc</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓37</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓28</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓33</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(mecanismo de interacción desconocido)</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de maraviroc</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de maraviroc</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓21</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de maraviroc</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg do</span><span style="font-family:Times New Roman; font-size:11pt">s veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de maraviroc.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANTIVIRALES PARA EL VHC</span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Inhibidores de la proteasa NS3/4A (IP)</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">boceprevir</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 % AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(mecanismo de interacción desconocido)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de boceprevir.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANTIMICROBIANOS</span></strong></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Antimicobacterianos</span></em></p></td></tr><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">rifampicina</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓61</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓38</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(inducción de la UGT1A1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">La rifampicina reduce las concentraciones plasmáticas de raltegravir. Si la administración simultánea con rifampicina es inevitable, se puede consid</span><span style="font-family:Times New Roman; font-size:11pt">erar duplicar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día).</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Extrapolado del estudio de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">No se recomienda la administración simultánea de raltegravir (1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día).</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">SEDANTES</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">midazolam</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de midazolam</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de midazolam</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de midazolam.</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Estos resultados indican que raltegravir no es un inductor ni un inhibidor de la CYP3A4, por</span><span style="font-family:Times New Roman; font-size:11pt">lo que no se prevé que raltegravir afecte a la farmacocinética de los fármacos que son sustratos de la CYP3A4.</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANTIÁCIDOS QUE CONTIENEN UN CATIÓN METÁLICO</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antiácido que contiene hidróxido de aluminio e hidróxido de magnesio</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">49</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">63</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">44</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">2</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">horas antes de la toma de raltegravir</span></span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">51</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">56</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">51</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">2</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">horas después de la toma de raltegravir</span></span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">57</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">6</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">horas antes de la toma de raltegravir</span></span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">6</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">horas después de la toma de raltegravir</span></span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">49</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(quelación de cationes metálicos)</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Los antiácidos que contienen aluminio y magnesio reducen los niveles plasmáticos de raltegravir. No se recomienda la administración simultánea de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día</span><span style="font-family:Times New Roman; font-size:11pt">)</span><span style="font-family:Times New Roman; font-size:11pt">con antiácidos que contienen aluminio y/o magnesio.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antiácido que contiene hidróxido de aluminio/magnesio</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">12</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">horas después de la toma de raltegravir</span></span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">58% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(quelación de iones metálicos)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antiácido que contiene carbonato de calcio</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">55</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">52</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(quelación de cationes metálicos)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir</span><span style="font-family:Times New Roman; font-size:11pt">(400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día).</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">antiácido que contiene carbonato de calcio</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dosis única)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">72</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">74</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">12</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">horas después de la toma de raltegravir</span></span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">57% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(quelación de iones metálicos)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No se recomienda la administración simultánea de raltegravir (1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una v</span><span style="font-family:Times New Roman; font-size:11pt">ez al día).</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10.5pt;">Otros CATIONES METÁLICOS</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:10.5pt;">Sales de hierro</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Previsto:</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Raltegravir</span><span style="font-family:Symbol; font-size:11pt">??</span><span style="font-family:Times New Roman; font-size:11pt">AUC</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(quelación de cationes metálicos)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:10.5pt">Se espera que la administración simultánea de sales de hierro reduzca los niveles plasmáticos de raltegravir; tomar las sales de hierro</span><span style="font-family:Times New Roman; font-size:10.5pt">al menos dos</span><span style="font-family:Times New Roman; font-size:10.5pt"> </span><span style="font-family:Times New Roman; font-size:10.5pt">horas después de la administración de raltegravir puede permitir limitar este efecto</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANTAGONISTAS H2 E INHIBIDORES DE LA BOMBA DE PROTONES</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">omeprazol</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">↑37</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">↑24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">↑51</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(aumento de la solubilidad)</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir</span><span style="font-family:Times New Roman; font-size:11pt">(</span><span style="font-family:Times New Roman; font-size:11pt">400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día</span><span style="font-family:Times New Roman; font-size:11pt">)</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">famotidina</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">↑44</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">↑6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de</span><span style="font-family:Times New Roman; font-size:11pt">raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">↑60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">(aumento de la solubilidad)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">medicamentos modificadores del pH gástrico:</span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">inhibidores de la bomba de protones (p. ej., omeprazol), antagonistas H2 (p. ej., famotidina, ranitidina, cimitedina)</span></p><p style="margin:0pt 0pt 0pt 10.75pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 0pt 0pt 10.75pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">El análisis farmacocinético poblacional mostró que el efecto de los medicamentos modificadores del pH gástrico sobre la farmacocinética de raltegravir era mínimo (disminución del 8,8% en la biodisponibilidad relativa), y no resultó ni estadística ni clínicamente significativo.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">(aumento de la solubilidad del medicamento)</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANTICONCEPTIVOS HORMONALES</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 11.7pt 0pt 16.5pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Etinilestradiol</span></strong></p><p style="margin:0pt 11.7pt 0pt 16.5pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Norelgestromina</span></strong></p><p style="margin:0pt 11.7pt 0pt 16.5pt"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↓2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de etinilestradiol</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de etinilestradiol</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% AUC de norelgestromina</span></p><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">↑29</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de norelgestromina</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.7pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de los anticonceptivos hormonales (a</span><span style="font-family:Times New Roman; font-size:11pt">base de estrógenos y/o de progesterona).</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">ANALGÉSICOS OPIOIDES</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:40%"><p style="margin:0pt 11.6pt 0pt 16.5pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">metadona</span></strong></p><p style="margin:0pt 11.6pt 0pt 16.5pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">(raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:29.98%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">↔ AUC de metadona</span></p><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">↔ C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de metadona</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:30.02%"><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">No es necesario ajustar la dosis de raltegravir (400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) ni de me</span><span style="font-family:Times New Roman; font-size:11pt">tadona.</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:179.55pt; border:none">
                                        </td>
                                        <td style="width:134.6pt; border:none">
                                        </td>
                                        <td style="width:134.75pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="426eda3c-ecce-4c50-9767-4ee94ac27cee"><title value="4.6. Fertilidad, embarazo y lactancia" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029811" /><display value="Fertilidad, embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Embarazo</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No hay datos relativos al uso de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día en mujeres embarazadas. Existe un elevado número de datos en mujeres embarazadas con exposición a raltegravir de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día durante el primer trimestre (datos prospectivos en más de 1.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">embarazos) que indican que no produce malformaciones. Los estudios realizados en animales han mostrado toxicidad para la reproducción (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.3).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Existen algunos datos en mujeres embarazadas con exposición a raltegravir de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día durante el segundo y/o tercer trimestre (datos prospectivos entre 300</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">embarazos) que indican que no hay un mayor riesgo de toxicidad fetal/neonatal.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se recomienda utilizar raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg durante el embarazo.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Registro de embarazos de las pacientes tratadas con antirretrovirales</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Para vigilar los resultados de la madre y el feto en pacientes a las que se les ha administrado inadvertidamente raltegravir durante el embarazo, se ha creado un Registro de embarazos de las pacientes tratadas con antirretrovirales. Se recomienda que los médicos incluyan a las pacientes en este registro.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Como regla general, cuando se decida utilizar antirretrovirales para el tratamiento de la infección por el VIH en mujeres embarazadas y consecuentemente reducir el riesgo de transmisión vertical del VIH al recién nacido, se deben tener en cuenta los datos en animales así como la experiencia clínica en mujeres embarazadas con el fin de caracterizar la seguridad para el feto.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Lactancia</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir/metabolitos se excretan en la leche materna en una proporción tal que se espera que tengan un efecto sobre los recién nacidos/niños lactantes. Los datos farmacodinámicos/toxicológicos disponibles en animales muestran que raltegravir/metabolitos se excretan en la leche (para mayor información ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.3).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se puede excluir el riesgo en recién nacidos/niños.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se recomienda que las mujeres que conviven con el VIH no den el pecho a sus hijos para evitar la transmisión del VIH.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Fertilidad</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observaron efectos sobre la fertilidad en ratas machos y hembras con dosis de hasta 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg/día que supusieron una exposición 3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces superior a la exposición observada para la dosis recomendada en humanos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="19c49ec6-85c7-4ad1-ab89-4d5683247fa7"><title value="4.7. Efectos sobre la capacidad para conducir y utilizar máquinas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029815" /><display value="Efectos sobre la capacidad para conducir y utilizar máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado mareos en algunos pacientes durante el tratamiento con regímenes que contienen raltegravir. Los mareos podrían afectar a la capacidad para conducir y utilizar máquinas en algunos pacientes (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.8).</span></p></div></text></section><section id="dceda235-79b8-48cf-86ee-8c7c29ace76e"><title value="4.8. Reacciones adversas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029816" /><display value="Reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resumen del perfil de seguridad</span></span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En ensayos clínicos aleatorizados, se administró raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día en combinación con pautas posológicas fijas o con un tratamiento de base optimizado a pacientes adultos no tratados previamente (N=547) y a pacientes adultos tratados previamente (N=462) durante 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas. Otros 531</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adultos no tratados previamente recibieron raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día con emtricitabina y tenofovir disoproxilo fumarato durante 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas. Ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Las reacciones adversas notificadas con mayor frecuencia durante el tratamiento fueron cefalea, náuseas y dolor abdominal. Las reacciones adversas graves notificadas con mayor frecuencia fueron el síndrome de reconstitución inmune y erupción. En ensayos clínicos, las tasas de interrupción del tratamiento con raltegravir debido a reacciones adversas fueron del 5% o inferiores.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">La rabdomiólisis fue una reacción adversa grave notificada con poca frecuencia en el uso poscomercialización de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces</span><span style="font-family:Times New Roman; font-size:11pt">al día.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tabla de reacciones adversas</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Las reacciones adversas consideradas por los investigadores causalmente relacionadas con raltegravir (solo o en combinación con otro ART), así como las reacciones adversas determinadas en la experiencia poscomercialización, se muestran a continuación, mediante Sistema de Clasificación de Órganos. La frecuencia de las reacciones adversas se define como frecuentes (≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/100 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/10), poco frecuentes (≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/1.000 a &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1/100) y frecuencia no conocida (no pueden estimarse a pa</span><span style="font-family:Times New Roman; font-size:11pt">rtir de los datos disponibles).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%"><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Sistema de Clasificación de Órganos</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Frecuencia</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Reacciones adversas</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Raltegravir</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">(solo o en combinación con otro ART)</span></strong></p></td></tr></thead><tbody><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Infecciones e infestaciones</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">herpes genital, foliculitis, gastroenteritis, herpes simple, infección por herpesvirus, herpes zoster, gripe, absceso en ganglio linfático, molusco contagioso, nasofaringitis, infección del tracto respiratorio superior</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Neoplasias benignas, malignas y no especificadas (incluidos quistes y pólipos)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">papiloma de piel</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos de la sangre y del sistema linfático</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">anemia, anemia por deficiencia de hierro, dolor en ganglios linfáticos, linfadenopatía, neutropenia, trombocitopenia</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del sistema inmunológico</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">síndrome de reconstitución inmune, hipersensibilidad medicamentosa, hipersensibilidad</span></p></td></tr><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del metabolismo y de la nutrición</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">disminución del apetito</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">caquexia, diabetes mellitus, dislipidemia, hipercolesterolemia, hiperglucemia, hiperlipidemia, hiperfagia, aumento del apetito, polidipsia, trastorno de grasa corporal</span></p></td></tr><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos psiquiátricos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">sueños extraños, insomnio, pesadilla, comportamiento anormal, depresión</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">trastorno mental, tentativa de suicidio, ansiedad, estado confusional, humor deprimido, depresión mayor, insomnio medio, alteración del humor, ataque de pánico, alteraciones del sueño, pensamiento suicida, comportamiento suicida (particularmente en pacientes con historia de enfermedad psiquiátrica preexistente)</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del sistema nervioso</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">mareos, cefalea, hiperactividad psicomotora</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">amnesia, síndrome del túnel carpiano, trastorno cognitivo, alteración de la atención, mareo postural, disgeusia, hipersomnio, hipoestesia, letargia, alteración de la memoria, migraña, neuropatía periférica, parestesia, somnolencia, cefalea tensional, temblores, sueño deficiente</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos oculares</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">deficiencia visual</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del oído y del laberinto</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">vértigo</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">tinnitus</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos cardíacos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">palpitaciones, bradicardia sinusal, extrasístoles ventriculares</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos vasculares</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">sofocos, hipertensión</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos respiratorios, torácicos y mediastínicos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">disfonía, epistaxis, congestión nasal</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos gastrointestinales</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">distensión abdominal, dolor abdominal, diarrea, flatulencia, náuseas, vómitos, dispepsia</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">gastritis, malestar abdominal, dolor abdominal superior, abdomen sensible, malestar anorrectal, estreñimiento, sequedad de boca, malestar epigástrico, duodenitis erosiva, eructación, reflujo gastroesofágico, gingivitis, glositis, odinofagia, pancreatitis aguda, úlcera péptica, hemorragia rectal</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos hepatobiliares</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">hepatitis, esteatosis hepática, hepatitis alcohólica, fallo hepático</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos de la piel y del tejido subcutáneo</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">erupción</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">acné, alopecia, dermatitis acneiforme, sequedad de piel, eritema, lipoatrofía facial, hiperhidrosis, lipoatrofia, lipodistrofia adquirida, lipohipertrofia, sudores nocturnos, prurigo, prurito, prurito generalizado, erupción macular, erupción maculo-papular, erupción prurítica, lesión cutánea, urticaria, xeroderma, síndrome de Stevens Johnson, erupción inducida por medicamento con eosinofilia y síntomas sistémicos (DRESS)</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos musculoesqueléticos y del tejido conjuntivo</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">artralgia, artritis, dolor de espalda, dolor en el costado, dolor musculoesquelético, mialgia, dolor de cuello, osteopenia, dolor en las extremidades, tendinitis, rabdomiólisis</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos renales y urinarios</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">insuficiencia renal, nefritis, nefrolitiasis, nocturia, quiste renal, deterioro renal, nefritis tubulointersticial</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del aparato reproductor y de la mama</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">disfunción eréctil, ginecomastia, síntomas menopáusicos</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Trastornos generales y alteraciones en el lugar de administración</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">astenia, cansancio, pirexia</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">malestar en el pecho, escalofríos, edema facial, aumento del tejido graso, sensación de nerviosismo, malestar, bulto submandibular, edema periférico, dolor</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Exploraciones complementarias</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">elevación de la alanina aminotransferasa, linfocitos atípicos, elevación de la aspartato aminotransferasa, elevación de los triglicéridos, elevación de la lipasa, elevación de la amilasa pancreática en sangre</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">reducción del recuento de neutrófilos absoluto, aumentos de la alcalina fosfatasa, disminución de la albúmina en sangre, elevación de la amilasa en sangre, elevación de la bilirrubina en sangre, elevación del colesterol en sangre, elevación de la creatinina en sangre, elevación de la glucosa en sangre, elevación del nitrógeno ureico en sangre, elevación de la creatinina fosfoquinasa, elevación en ayunas de la glucosa en sangre, presencia de glucosa en orina, elevación de las lipoproteínas de alta densidad, elevación del ratio internacional normalizado, elevación de las lipoproteínas de baja densidad, reducción del recuento de plaquetas, eritrocitos en orina positivo, aumento de la circunferencia de la cintura, aumento de peso, disminución del recuento leucocitario</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Lesiones traumáticas, intoxicaciones y complicaciones de procedimientos terapéuticos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.82%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.84%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">sobredosificación accidental</span></p></td></tr></tbody></table><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Descripción de reacciones adversas seleccionadas</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En los estudios de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, se han notificado casos de cáncer en los pacientes tratados previamente y en pacientes no tratados previamente que recibieron raltegravir junto con otros agentes antirretrovirales. Los tipos y tasas de cáncer fueron los esperados en una población con inmunodeficiencia intensa. El riesgo de desarrollar cáncer en estos estudios fue similar en los grupos que recibieron raltegravir y en los grupos que recibieron los agentes de comparación.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Se observaron valores analíticos anormales en la creatinina quinasa de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">4 en pacientes tratados con raltegravir. Se han notificado casos de miopatía y rabdomiólisis. Utilizar con precaución en pacientes que hayan tenido en el pasado miopatía o rabdomiólisis o que tengan cualquier factor desencadenante, incluyendo otros medicamentos asociados a estas enfermedades (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Se han notificado casos de osteonecrosis, especialmente en pacientes con factores de riesgo normalmente reconocidos, con infección por el VIH avanzada o exposición a largo plazo al tratamiento antirretroviral de combinación (TARC). Se desconoce la frecuencia (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Al inicio del tratamiento antirretroviral de combinación (TARC) se puede originar una reacción inflamatoria como consecuencia de infecciones oportunistas asintomáticas o residuales en pacientes infectados por el VIH con deficiencia inmunitaria grave. También se han notificado trastornos autoinmunitarios (como por ejemplo la enfermedad de Graves</span><span style="font-family:Times New Roman; font-size:11pt">y la hepatitis autoinmune</span><span style="font-family:Times New Roman; font-size:11pt">); sin embargo, el tiempo notificado hasta su aparición es más variable y estos acontecimientos pueden suceder muchos meses después del inicio del tratamiento (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Al menos hubo un caso grave para cada una de las siguientes reacciones adversas clínicas: herpes genital, anemia, síndrome de reconstitución inmune, depresión, trastorno mental, tentativa de suicidio, gastritis, hepatitis, insuficiencia renal, sobredosificación accidental.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos clínicos con pacientes tratados previamente, independientemente de la causalidad, se observó erupción con más frecuencia en regímenes que contenían raltegravir y darunavir en comparación con aquellos que contenían raltegravir sin darunavir o darunavir sin raltegravir. La erupción considerada por el investigador como relacionada con el medicamento se produjo en tasas similares. Las tasas de exposición ajustada de erupción (todas las causas) fueron 10,9; 4,2 y 3,8 por 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes-año (PYR) respectivamente; y para la erupción relacionada con el medicamento fueron 2,4; 1,1 y 2,3 por 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">PYR respectivamente. Las erupciones observadas en los ensayos clínicos fueron de gravedad leve a moderada y no hubo que interrumpir el tratamiento (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.4).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes co</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">‑</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">infectados con el virus de la hepatitis</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">B y/o el virus de la hepatitis</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">C</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En ensayos clínicos, hubo 79</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectados con hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B, 84</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectados con hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C y 8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectados con hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B y C que fueron tratados con raltegravir en combinación con otros medicamentos para el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1. En general, el perfil de seguridad de raltegravir en los pacientes co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectados con el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B y/o el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C fue similar al observado en los pacientes sin co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infección con el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B y/o el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C, aunque las tasas de valores anormales de AST y ALT eran algo mayores en el subgrupo co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectado con el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B y/o el virus de la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">C.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">A las 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas, en los pacientes tratados previamente, los valores analíticos anormales de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 o superiores, que representan un grado de empeoramiento respecto al basal en la AST, ALT o en la bilirrubina total, se produjeron en el 29</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 34</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y 13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, respectivamente, de los pacientes co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectados tratados con raltegravir, en comparación con el 11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y 9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% del resto de los pacientes tratados con raltegravir. A las 240</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas, en los pacientes no tratados previamente, los valores analíticos anormales de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 o superiores, que representan un grado de empeoramiento respecto al basal en los valores de AST, ALT o en la bilirrubina total, se produjeron en el 22</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 44</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, respectivamente, de los pacientes co</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">infectados tratados con raltegravir, en comparación con el 13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, 13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y 5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% del resto de los pacientes tratados con raltegravir.</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">La formulación de ISENTRESS 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos no se ha estudiado en pacientes pediátricos (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Niños y adolescentes de 2 a 18</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">años de edad</span></em></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Raltegravir dos veces al día ha sido estudiado en 126</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">niños y adolescentes de 2 a 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 y tratados previamente con antirretrovirales, en combinación con otros antirretrovirales en el ensayo IMPAACT</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">P1066 (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.1 y 5.2). De los 126</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes, 96 recibieron la dosis recomendada de raltegravir dos veces al día.</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">En estos 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">niños y adolescentes, la frecuencia, el tipo y la gravedad de las reacciones adversas relacionadas con el medicamento en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 fueron comparables a las observadas en adultos.</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Un paciente experimentó reacciones adversas clínicas relacionadas con el medicamento de hiperactividad psicomotora de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3, comportamiento anormal e insomnio; un paciente experimentó una erupción alérgica grave de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 relacionada con el medicamento.</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Un paciente experimentó alteraciones de laboratorio relacionadas con el medicamento, alteraciones de los niveles de la AST de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 y de la ALT de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3, las cuales se consideraron graves.</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Lactantes de 4</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">semanas a menos de 2</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">años de edad</span></em></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Raltegravir dos veces al día ha sido estudiado también en 26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">lactantes de 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas a menos de 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, en combinación con otros agentes antirretrovirales en el ensayo IMPAACT</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">P1066 (ver las secciones</span><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><span style="font-family:Times New Roman; font-size:11pt">5.1 y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2).</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">En estos 26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">lactantes, la frecuencia, el tipo y la gravedad de las reacciones adversas relacionadas con el medicamento hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 fueron comparables a las observadas en adultos.</span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.6pt 0pt 0pt"><span style="font-family:Times New Roman; font-size:11pt">Un paciente experimentó una erupción alérgica grave de grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3 relacionada con el medicamento que condujo a la suspensión del tratamiento.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><em><span style="font-family:Times New Roman; font-size:11pt;">Recién nacidos expuestos al VIH</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">‑</span></em><em><span style="font-family:Times New Roman; font-size:11pt;">1</span></em></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En el ensayo IMPAACT</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">P1110 (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.2), los lactantes elegibles tenían al menos 37</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de gestación y pesaban un mínimo de 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg. Dieciséis (16)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">recién nacidos recibieron 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">dosis de ISENTRESS en las primeras 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de vida y 26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">recién nacidos recibieron la dosis diaria durante 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas; todos tuvieron un seguimiento de 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas. No hubo experiencias clínicas adversas relacionadas con el medicamento y sí hubo tres experiencias adversas relacionadas con el medicamento en las pruebas de laboratorio (una neutropenia transitoria de Grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 en un paciente que recibió zidovudina para la prevención de la transmisión de madre a hijo (PTMH) y dos elevaciones de la bilirrubina (una de Grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y otra de Grado</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2) que no se consideraron graves y no requirieron tratamiento específico).</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text><section id="8165b45d-347b-4a6e-8a1c-1218c9241c59"><title value="4.8.2. Notificación de sospechas de reacciones adversas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029818" /><display value="Notificación de sospechas de reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante notificar sospechas de reacciones adversas al medicamento tras su autorizaci</span><span style="font-family:Times New Roman; font-size:11pt">ón. Ello permite una supervisión continuada de la relación beneficio/riesgo del medicamento. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas a través del</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#bfbfbf">sistema nacional de notificación incluido en el</span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; background-color:#bfbfbf">Apéndice</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; background-color:#bfbfbf"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; background-color:#bfbfbf">V</span></span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p></div></text></section></section><section id="313fa764-9b75-4b7c-aae5-3f9bc19fe224"><title value="4.9. Sobredosis" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029819" /><display value="Sobredosis" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se dispone de información específica sobre el tratamiento en el caso de sobredosis de raltegravir.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En caso de sobredosis, es razonable emplear las medidas convencionales de soporte; por ejemplo, eliminar el material no absorbido del tracto gastrointestinal, llevar a cabo una vigilancia clínica (que incluya la realización de un electrocardiograma) e instaurar un tratamiento de soporte si es necesario. Se debe tener en cuenta que raltegravir se presenta para uso clínico en forma de la sal de potasio. Se desconoce en qué medida se puede dializar raltegravir.</span></p></div></text></section></section><section id="fddec125-2547-4d8a-b4d9-5e8564ce65b8"><title value="5. Propiedades farmacológicas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029821" /><display value="Propiedades farmacológicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="729c516a-c955-4658-bfc2-8503f4be7268"><title value="5.1. Propiedades farmacodinámicas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029822" /><display value="Propiedades farmacodinámicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Grupo farmacoterapéutico: antiviral para uso sistémico, inhibidores de la integrasa, código ATC:</span><span style="font-family:Times New Roman; font-size:11pt">J05AJ01</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Mecanismo de acción</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir es un inhibidor de la transferencia de las hebras de la integrasa que es activo frente al virus de la inmunodeficiencia humana (VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1). Raltegravir inhibe la actividad catalítica de la integrasa, una enzima codificada por el VIH y necesaria para la replicación viral. La inhibición de la integrasa evita la inserción covalente o integración del genoma del VIH en el genoma de la célula huésped. Los genomas del VIH que no se integran no pueden dirigir la producción de nuevas partículas virales infecciosas, por lo que inhibir la integración evita la propagación de la infección viral.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Actividad antiviral</span></span><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></span></em></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir en concentraciones de 31</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM inhibió en un 95%</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(IC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">95</span><span style="font-family:Times New Roman; font-size:11pt">) la replicación del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 (relativo a un cultivo infectado por virus no tratado) en cultivos de linfocitos</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">T humanos infectados por la variante H9IIIB del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 adaptada a la línea celular. Además, raltegravir inhibió la replicación viral en cultivos de monocitos humanos de sangre periférica activados por mitógenos e infectados por diversos aislados clínicos primarios del VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1, entre ellos aislados de 5 subtipos no B y aislados resistentes a inhibidores de la transcriptasa inversa e inhibidores de la proteasa. En un ensayo de infección monociclo, raltegravir inhibió la infección de 23 aislados del VIH que representaban 5 subtipos no B y 5 formas recombinantes circulantes con valores IC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">que oscilaban desde 5 hasta 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resistencia</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La mayoría de los virus aislados de pacientes en los que ha fracasado raltegravir mostraban un elevado nivel de resistencia a raltegravir como consecuencia de la aparición de dos o más mutaciones en la integrasa. La mayoría presentaba una mutación en el aminoácido de la posición 155</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(N155 cambio por H), en el aminoácido de la posición 148</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(Q148 cambio por H, K o R) o en el aminoácido de la posición 143</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(Y143 cambio por H, C o R) y una o más mutaciones adicionales de la integrasa (por ej., L74M, E92Q, T97A, E138A/K, G140A/S, V1511, G163R y S230R). Las mutaciones reducen la susceptibilidad del virus a raltegravir y la adición de otras mutaciones disminuye aún más la susceptibilidad a raltegravir. Los factores que reducían la probabilidad de desarrollar resistencia eran una carga viral baja en el período basal y el uso de otros antirretrovirales activos. Las mutaciones que confieren resistencia a raltegravir generalmente también confieren resistencia a elvitegravir, un inhibidor de la transferencia de las hebras mediada por la integrasa. Las mutaciones en el aminoácido</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">143 confieren mayor resistencia a raltegravir que a elvitegravir y la mutación E92Q confiere mayor resistencia a elvitegravir que a raltegravir. Los virus que albergan una mutación en el aminoácido</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">148, junto con una o más mutaciones adicionales de resistencia a raltegravir, pueden tener también resistencia clínicamente significativa a dolutegravir.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Experiencia clínica</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La evidencia de la eficacia de raltegravir se basó en el análisis de los datos de 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de dos ensayos aleatorizados, doble ciego, controlados con placebo (BENCHMRK</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y BENCHMRK</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2, Protocolos 018 y 019) en pacientes adultos infectados con el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 tratados previamente con antirretrovirales, en el análisis de los datos de 240</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de un ensayo aleatorizado, doble ciego, controlado con principio activo (STARTMRK, Protocolo 021) en pacientes adultos infectados con el VIH-1 no tratados previamente con antirretrovirales y en el análisis de los datos de 96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de un ensayo aleatorizado, doble ciego, controlado con principio activo (ONCEMRK, protocolo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">292) en pacientes adultos infectados por el VIH-1 no tratados previamente con antirretrovirales.</span></p><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Eficacia</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos tratados previamente (400</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">mg dos veces al día)</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los ensayos BENCHMRK</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y BENCHMRK</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 (ensayos multicéntricos, aleatorizados, a doble ciego, controlados con placebo) evaluaron la seguridad y la actividad antirretroviral de raltegravir en dosis de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día frente al placebo en una combinación con TBO, en pacientes infectados por el VIH, de 16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad o mayores, con resistencia documentada a por lo menos 1 fármaco de cada una de las 3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">clases de tratamientos antirretrovirales (INTI, INNTI e IP). Antes de la aleatorización, el investigador eligió el TBO para cada paciente basándose en los tratamientos previos que había recibido el paciente y en los resultados de las pruebas de resistencia viral genotípica y fenotípica en el período basal.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los datos demográficos (sexo, edad y raza) y las características basales de los pacientes de los grupos que recibieron raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y placebo eran similares. Los pacientes habían recibido previamente una mediana de 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">antirretrovirales durante una mediana de 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años. En el TBO se usó una mediana de 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">antirretrovirales.</span></p><p style="margin:0pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Análisis de los resultados a las 48 y 96</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">semanas</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los resultados duraderos (semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 y semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96) agrupados de los pacientes que recibieron la dosis recomendada de raltegravir de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día en los estudios BENCHMRK</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y BENCHMRK</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 se muestran en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">2</span></strong></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Resultados de eficacia en las semanas</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48 y 96</span></strong></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:102.02%" ><thead><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Estudios BENCHMRK 1 y 2 agrupados</span></strong></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Parámetro</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-indent:-51.4pt; text-align:center; page-break-after:avoid; padding-left:51.4pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">48</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">Semanas</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-indent:-51.4pt; text-align:center; page-break-after:avoid; padding-left:51.4pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">96</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">Semanas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Raltegravir</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">mg</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">dos veces al día + TBO</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N = 462)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Placebo</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">+</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">TBO</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N = 237)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Raltegravir</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">mg</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">dos veces al día + TBO</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N = 462)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Placebo + TBO</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N = 237)</span></strong></p></td></tr></thead><tbody><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Porcentaje de ARN del VIH</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">&lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">%)</span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">72 (68, 76)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">37 (31, 44)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">62 (57, 66)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">28 (23, 34)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">Características basal</span><span style="font-family:Times New Roman; font-size:10pt">es</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH &gt; 100.000 copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">62 (53, 69)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">17 (9, 27)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">53 (45, 61)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">15 (8, 25)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">≤ 100.000 copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">82 (77, 86)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">49 (41, 58)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">74 (69, 79)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">39 (31, 47)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">Recuento de CD4 ≤ 50 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">61 (53, 69)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">21 (13, 32)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">51 (42, 60)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">14 (7, 24)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">&gt; 50 y ≤ 200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">80 (73, 85)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">44 (33, 55)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">70 (62, 77)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">36 (25, 48)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">&gt; 200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">83 (76, 89)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">51 (39, 63)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">78 (70, 85)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">42 (30, 55)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Puntuación de sensibilidad (PSG)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">§</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">52 (42, 61)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">8 (3, 17)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">46 (36, 56)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">5 (1, 13)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">81 (75, 87)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">40 (30, 51)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">76 (69, 83)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">3</span><span style="font-family:Times New Roman; font-size:10pt">1 (22, 42)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">2 y más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">84 (77, 89)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">65 (52, 76)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">71 (63, 78)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">56 (43, 69)</span></p></td></tr><tr><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Porcentaje de ARN del VIH</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">&lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">50</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">%)</span></strong></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt 0pt 0pt 14.2pt"><span style="font-family:Times New Roman; font-size:10pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">62 (57, 67)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">33 (27, 39)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">57 (52, 62)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">26 (21, 32)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt 0pt 0pt 28.35pt"><span style="font-family:Times New Roman; font-size:10pt">Características basales</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH &gt; 100.000 copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">48 (40, 56)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">16 (8, 26)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">47 (39, 55)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">13 (7, 23)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">≤ 100.000 copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">73 (68, 78)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">43 (35, 52)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">70 (64, 75)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">36 (28, 45)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">Recuento de CD4 ≤ 50 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">50 (41, 58)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">20 (12, 31)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">50 (41, 58)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">13 (6, 22)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">&gt; 50 y ≤ 200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">67 (59, 74)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">39 (28, 50)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">65 (57, 72)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">32 (22, 44)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">&gt; 200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">76 (68, 83)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">44</span><span style="font-family:Times New Roman; font-size:10pt">(32, 56)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">71 (62, 78)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">41 (29, 53)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Puntuación de sensibilidad (PSG)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">§</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">45 (35, 54)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">3 (0, 11)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">41 (32, 51)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">5 (1, 13)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">67 (59, 74)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">37 (27, 48)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">72 (64, 79)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">28 (19, 39)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">2 y más</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">75 (68, 82)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">59 (46, 71)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">65 (56, 72)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">53 (40, 66)</span></p></td></tr><tr><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Cambio medio en el recuento de células CD4 (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">%), células/mm</span></strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt 0pt 0pt 14.2pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">109 (98, 121)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">45 (32, 57)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">123 (110, 137)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">49 (35, 63)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt 0pt 0pt 28.35pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Características basales</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH &gt; 100.000 copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">126 (107, 144)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">36 (17, 55)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">140 (115, 165)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">40 (16, 65)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">≤ 100.000 copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">100 (86, 115)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">49 (33, 65)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">114 (98, 131)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">53 (36, 70)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Recuento de CD4 ≤ 50 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-indent:-0.05pt; text-align:center; page-break-after:avoid; padding-left:0.05pt"><span style="font-family:Times New Roman; font-size:10pt">121 (100, 142)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">33 (18, 48)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">130 (104, 156)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">42 (17, 67)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">&gt; 50 y ≤ 200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">104 (88, 119)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">47 (28, 66)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">123 (103, 144)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">56 (34, 79)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">&gt; 200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">104 (80, 129)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">54 (24, 84)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">117 (90, 143)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">48 (23, 73)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Puntuación de sensibilidad (PSG)</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">§</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">0</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">81 (55, 106)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">11 (4, 26)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">97 (70, 124)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">15 (-0, 31)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">1</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">113 (96, 130)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">44 (24, 63)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">132 (111, 154)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">45 (24, 66)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.76%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">2 o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.38%"><p style="margin:0pt; text-indent:-0.05pt; text-align:center; page-break-after:avoid; padding-left:0.05pt"><span style="font-family:Times New Roman; font-size:10pt">125 (105, 144)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.42%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">76 (48, 103)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.06%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">134 (108, 159)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.38%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">90 (57, 123)</span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-indent:-11.05pt; page-break-after:avoid; padding-left:11.05pt"><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span><span style="font-family:Times New Roman; font-size:10pt">             </span><span style="font-family:Times New Roman; font-size:10pt">Los pacientes que no completaron el tratamiento se consideraron fracasos: se consideró que en los pacientes que se retiraron prematuramente el tratamiento habría fracasado después. Se comunican los porcentajes de pacientes con respuesta y los intervalos de confianza (IC) del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% correspondiente.</span></p><p style="margin:0pt; text-indent:-11.05pt; page-break-after:avoid; padding-left:11.05pt"><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></strong><span style="font-family:Times New Roman; font-size:10pt">             </span><span style="font-family:Times New Roman; font-size:10pt">Para los análisis por factores pronósticos, los fracasos virológicos fueron arrastrados para porcentajes &lt;400 y 50 copias/ml. Para los cambios medios en el recuento de células CD4 se usó el valor basal arrastrado para los fracasos virológicos.</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; page-break-inside:avoid; page-break-after:avoid; padding-left:8pt"><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">§</span><span style="font-family:Times New Roman; font-size:10pt">             </span><span style="font-family:Times New Roman; font-size:10pt">La puntuación de sensibilidad genotípica (PSG) se definió como el número total de ART orales en el tratamiento de base optimizado (TBO) frente a los cuales el aislado viral de un paciente fue sensible desde el punto de vista genotípico según los resultados de las pruebas de resistencia genotípica. El uso de enfuvirtida en TBO en los pacientes no tratados previamente con enfuvirtida se consideró como un fármaco activo en TBO. Asimismo, el uso de darunavir en TBO en los pacientes no tratados previamente con darunavir se consideró como un fármaco activo en TBO.</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:160.55pt; border:none">
                                        </td>
                                        <td style="width:71.05pt; border:none">
                                        </td>
                                        <td style="width:80.45pt; border:none">
                                        </td>
                                        <td style="width:69.55pt; border:none">
                                        </td>
                                        <td style="width:80.25pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir alcanzó unas respuestas virológicas (utilizando la aproximación No finalización=Fracaso) de unas concentraciones de ARN del VIH de &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml en el 61,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de los pacientes en la semana 16, del 62,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% en la semana 48 y del 57,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% en la semana 96. Algunos pacientes experimentaron recaída virológica entre la semana 16 y la semana 96. Los factores asociados al fracaso son carga viral alta en el período basal y TBO que no incluyese al menos un agente activo potente.</span></p><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Cambio a raltegravir (400</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">mg dos veces al día)</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los estudios SWITCHMRK 1 y 2 (Protocolos 032 y 033) evaluaron a pacientes infectados con el VIH que recibían tratamiento supresor (ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml en la selección; régimen estable</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses) con lopinavir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ritonavir 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos dos veces al día más al menos 2 inhibidores nucleósidos de la transcriptasa inversa y que se aleatorizaron 1:1 para continuar con lopinavir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ritonavir 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos dos veces al día (n=174 y n=178, respectivamente) o para sustituir lopinavir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ritonavir con raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día (n=174 y n=176, respectivamente). No se excluyeron los pacientes con antecedentes de fracaso virológico y no se limitó el número de tratamientos antirretrovirales previos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Estos estudios se cancelaron después del análisis de eficacia principal en la semana 24 puesto que no lograron demostrar la no inferioridad de raltegravir frente a lopinavir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ritonavir. En ambos estudios, en la semana 24, la supresión del ARN del VIH hasta menos de 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml se mantuvo en el 84,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% del grupo de raltegravir frente al 90,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% del grupo de lopinavir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">ritonavir, (no finalización=fracaso). Ver la sección 4.4 referente a la necesidad de administrar raltegravir con otros dos agentes activos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos no tratados previamente (400</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">mg dos veces al día)</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">STARTMRK (ensayo multicéntrico, aleatorizado, doble ciego, controlado con tratamiento activo) evaluó la seguridad y actividad antirretroviral de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día frente a efavirenz 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg al acostarse, en una combinación con emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato, en pacientes infectados con el VIH no tratados previamente con AR</span><span style="font-family:Times New Roman; font-size:11pt">N del VIH</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml. La aleatorización se estratificó en la selección según las concentraciones de ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(≤50.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&gt;50.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml) y el estatus de hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B o C (positivo o negativo).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los datos demográficos del paciente (sex</span><span style="font-family:Times New Roman; font-size:11pt">o, edad y raza) y las características basales eran comparables entre el grupo que recibía raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día y el grupo que recibía efavirenz 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg al acostarse.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Resultados del análisis de 48 y 240</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">semanas</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En cuanto a la variable principal de eficacia, la proporción de pacientes que alcanzan ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 fue 241/280 (86,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) en el grupo que recibía raltegravir y 230/281 (81,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) en el grupo que recibía efavirenz. La diferencia en el tratamiento (raltegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">efavirenz) fue 4,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% con el correspondiente IC del 95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de (-1,9; 10,3) que establece que raltegravir no es inferior a efavirenz (valor p para la no inferioridad</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001). A la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">240, la diferencia de tratamiento (raltegravir– efavirenz) fue 9,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% con el correspondiente IC del 95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de (1,7; 17,3). Los resultados de las semanas</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 y 240 para los pacientes que recibían la dosis recomendada de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día de STARTMRK se muestran en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">3</span></strong></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Resultado de eficacia en las semanas</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48 y 240</span></strong></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><thead><tr style="height:12.6pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Estudio STARTMRK</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Parámetro</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">48</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">Semanas</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">240</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">Semanas</span></strong></p></td></tr><tr style="height:12.6pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Raltegravir</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">mg dos veces al día</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">281)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt 0pt 0pt 1.35pt; text-indent:-50.05pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; padding-left:50.05pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Efavirenz</span></strong></p><p style="margin:0pt 0pt 0pt 1.35pt; text-indent:-5.2pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; padding-left:5.2pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">600</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">mg al acostarse</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">282)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Raltegravir</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">mg dos veces al día</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">281)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1.5pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt 0pt 0pt 1.35pt; text-indent:-50.05pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; padding-left:50.05pt"><strong><span style="font-family:Times New Roman; font-size:10pt;">Efavirenz</span></strong></p><p style="margin:0pt; text-indent:1.35pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">600</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">mg al acostarse</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">(N</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">282)</span></strong></p></td></tr></thead><tbody><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Porcentaje del ARN del VIH &lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">50</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">copias/ml (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">%)</span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">86 (81, 90)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">82 (77, 86)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">71 (65, 76)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">61 (55, 67)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Característica basal</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH &gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">91 (85, 95)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">89 (83, 94)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">70 (62, 77)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt">65 (56, 72)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 56.7pt"><span style="font-family:Times New Roman; font-size:10pt">≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">93 (86, 97)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">89 (82, 94)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">72 (64, 80)</span></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">58 (49, 66)</span></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">Recuento CD4 ≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">84 (64, 95)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">86 (67, 96)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">58 (37, 77)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">77 (58, 90)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 49.65pt"><span style="font-family:Times New Roman; font-size:10pt">&gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50 y ≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">200 células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">89 (81, 95)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">86 (77, 92)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">67 (57, 76)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">60 (50, 69)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 49.65pt"><span style="font-family:Times New Roman; font-size:10pt">&gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">200</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">94 (89, 98</span><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">92 (87, 96)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">76 (68, 82)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">60 (51, 68)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:10pt">Subtipo viral Clado B</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">90 (85, 94)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">89 (83, 93)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">71 (65, 77)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">59 (52, 65)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 56.7pt"><span style="font-family:Times New Roman; font-size:10pt">Clado no B</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">96 (87, 100)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">91 (78, 97)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">68 (54, 79)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">70 (54, 82)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Media del cambio en linfocitos CD4 (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">%), células/mm</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></strong></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">189 (174, 204)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">163 (148, 178)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">374 (345, 403)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">312 (284, 339)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Característica basal</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">ARN del VIH &gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">196 (174, 219)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">192 (169, 214)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">392 (350, 435)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">329 (293, 364)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 56.7pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">100.000</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">180 (160, 200)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">134 (115, 153)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">350 (312, 388)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">294 (251, 337)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Recuento CD4 ≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">170 (122, 218)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">152 (123, 180)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">304 (209, 399)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">314 (242, 386)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 49.65pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">&gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">50 y ≤</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">200</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">193 (169, 217)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">175 (151, 198)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">413 (360, 465)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">306 (264,</span><span style="font-family:Times New Roman; font-size:10pt">348)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 49.65pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">&gt;</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">200</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">células/mm</span><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">3</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">190 (168, 212)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">157 (134, 181)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">358 (321, 395)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">316 (272, 359)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Subtipo viral Clado B</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">187 (170, 204)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">164 (147, 181)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">380 (346, 414)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">303 (272, 333)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:37.66%"><p style="margin:0pt 0pt 0pt 56.7pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Clado no B</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:14.66%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">189 (153, 225)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.32%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">156 (121, 190)</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:15.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">332 (275, 388)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:16.86%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">329 (260, 398)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt"> </span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:3.5pt; padding-right:3.5pt; vertical-align:top"><p style="margin:0pt; text-indent:-7.95pt; page-break-after:avoid; padding-left:7.95pt"><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span><span style="font-family:Times New Roman; font-size:10pt">Los pacientes que no completaron el tratamiento se consideraron fracasos: se consideró que en los pacientes que se retiraron prematuramente el tratamiento habrían fracasado después. Se comunican los porcentajes de pacientes con respuesta y los intervalos de confianza (IC) del 95</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">% correspondiente.</span></p><p style="margin:0pt; text-indent:-7.95pt; page-break-after:avoid; padding-left:7.95pt"><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">‡</span><span style="font-family:Times New Roman; font-size:10pt">Para los análisis por factores pronósticos, los fracasos virológicos fueron arrastrados para porcentajes &lt;50 y 400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">copias/ml. Para los cambios medios en el recuento de células CD4 se usó el valor basal arrastrado para los fracasos virológicos.</span></p><p style="margin:0pt; text-indent:-7.95pt; page-break-after:avoid; padding-left:7.95pt"><span style="font-family:Times New Roman; font-size:10pt">Notas: Los análisis están basados en todos los datos disponibles.</span></p><p style="margin:0pt; text-indent:-8pt; padding-left:8pt"><span style="font-family:Times New Roman; font-size:10pt">Raltegravir y efavirenz se administraron con emtricitabina</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">(+)</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">tenofovir disoproxilo fumarato.</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:169.05pt; border:none">
                                        </td>
                                        <td style="width:65.8pt; border:none">
                                        </td>
                                        <td style="width:68.75pt; border:none">
                                        </td>
                                        <td style="width:69.6pt; border:none">
                                        </td>
                                        <td style="width:75.7pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes adultos no tratados previamente (1.200</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">mg [2 x 600</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">mg] una vez al día)</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio ONCEMRK (ensayo multicéntrico, aleatorizado, doble ciego, controlado con principio activo; Protocolo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">292</span><span style="font-family:Times New Roman; font-size:11pt">)</span><span style="font-family:Times New Roman; font-size:11pt">se evaluaron la seguridad y la actividad antirretroviral de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día + emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato frente a raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, en combinación con emtricitabina</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(+)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tenofovir disoproxilo fumarato, en pacientes infectados por el VIH no tratados previamente, con ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1.000 copias/m</span><span style="font-family:Times New Roman; font-size:11pt">l</span><span style="font-family:Times New Roman; font-size:11pt">. La aleatorización se</span><span style="font-family:Times New Roman; font-size:11pt">estratificó según las concentraciones de ARN del VIH (≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/m</span><span style="font-family:Times New Roman; font-size:11pt">l</span><span style="font-family:Times New Roman; font-size:11pt">; y &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100.000</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/m</span><span style="font-family:Times New Roman; font-size:11pt">l</span><span style="font-family:Times New Roman; font-size:11pt">) y por el estatus de hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B o C (positivo o negativo).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Los datos demográficos del paciente (sexo, edad y raza) y las características basales eran compar</span><span style="font-family:Times New Roman; font-size:11pt">ables entre el grupo que recibía raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y el grupo que recibía raltegravir</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt; page-break-inside:avoid; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Resultados de los análisis a las 48 y 96</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">semanas</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En lo que respecta a la variable principal de eficacia, la proporción de pacientes que alcanzan ARN del VIH &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/m</span><span style="font-family:Times New Roman; font-size:11pt">l</span><span style="font-family:Times New Roman; font-size:11pt">en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 fue 472/531(88,9%) en el grupo que recibía raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y 235/266 (88,3%) en el grupo que recibía raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día. La diferencia entre los tratamientos (raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día-raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día) fue del 0,5%, con un IC del 95% asociado de (-4,2; 5,2), que establece que raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día es no inferior a raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96, la proporción de pacientes que alcanzaron ARN del VIH</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">copias/ml fue de 433/531 (81,5%) en el grupo que recibió raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día y de 213/266 (80,1%) en el grupo que recibió raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día. La diferencia de tratamiento (raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día-raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día) fue del 1,5% con un IC asociado del 95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de (-4,4; 7,3). Los resultados de la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">96 del ensayo ONCEMRK se muestran en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.</span></p><p style="margin:0pt; text-indent:-28.35pt; padding-left:28.35pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">4</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Resultado de eficacia en las semanas</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">48 y 96</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:112.16%" ><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Ensayo ONCEMRK</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">             </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Parámetro</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:9pt;">48</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">semanas</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:9pt;">96</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">semanas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Raltegravir</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">600</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">mg (1.200</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">mg</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">una vez al día)</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:9pt;">(N=531)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Raltegravir</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">mg</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">dos veces al día</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:9pt;">(N=266)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Raltegravir</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">600</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">mg (1.200</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">mg</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">una vez al día)</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:9pt;">(N=531)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Raltegravir</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">400</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">mg</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">dos veces al día</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:9pt;">(N=266)</span></strong></p></td></tr><tr style="height:23.35pt"><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:9pt;">Porcentaje del ARN del VIH &lt;</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">copias/ml (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">%)</span></strong></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">†</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">88,9 (85,9; 91,4)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">88,3 (83,9; 91,9)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">81,5 (78,0; 84,8)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">80,1 (74,8; 84,7)</span></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Característica basal</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">‡</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">ARN del VIH</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">&gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">86,7 (80,0; 91,8)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">83,8 (73,4; 91,3)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">84,7 (77,5; 90,3)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">82,9 (72,0; 90,8)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">97,2 (94,9; 98,7)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">97,7 (94,3; 99,4)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">91,9 (88,5; 94,5)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">93,0 (89,1; 97,1)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Recuento CD4</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">200</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/mm</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">85,1 (74,3; 92,6)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0.75pt 0.05pt 0.75pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">87,9 (71,8; 96,6)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">79,0 (66,8; 88,3)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">80 (61,4; 92,3)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">&gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">200</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/mm</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">95,6 (93,2; 97,3)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0.75pt 0.05pt 0.75pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">94,5 (90,6; 97,1)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">91,4 (88,3; 93,9)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">92,2 (87,6; 95,5)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Subtipo viral Clado B</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">94,6 (91,4; 96,8)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0.75pt 0.05pt 0.75pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">93,7 (89,0; 96,8)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">90,0 (86,0; 93,2)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">88,9 (83,0; 93,3)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Clado no B</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">93,6 (89,1; 96,6)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0.75pt 0.05pt 0.75pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">93,2 (84,9; 97,8)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">89,5 (84,1; 93,6)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt">94,4 (86,2; 98,4)</span></p><p style="margin:0pt 0.05pt 0pt 0pt; text-indent:-8pt; text-align:center; padding-left:8pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:9pt;">Media del cambio en linfocitos CD4 (IC del 95</span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:9pt;">%), células/mm</span></strong><strong><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">3</span></strong></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Todos los pacientes</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">‡</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">232 (215; 249)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">234 (213; 255)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">262 (243; 280)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">262 (236; 288)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Característica basal</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">‡</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">ARN del VIH</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">&gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">276 (245; 308)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">256 (218; 294)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">297 (263; 332)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">281 (232; 329)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">100.000</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">214 (194; 235)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">225 (199; 251)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">248 (225; 270)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">254 (224; 285)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Recuento CD4</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">≤</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">200</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/mm</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">209 (176; 243)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">209 (172; 245)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">239 (196; 281)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">242 (188; 296)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">&gt;</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">200</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">células/mm</span><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">235 (216; 255)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">238 (214; 262)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">265 (245; 286)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center"><span style="font-family:Times New Roman; font-size:9pt">265 (237; 294)</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Subtipo viral Clado B</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">232 (209; 254)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">240 (213; 266)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">270 (245; 296)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">267 (236; 297)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:33.34%"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">Clado no B</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">233 (205; 261)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.24%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">226 (191; 261)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.64%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">246 (219; 274)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.82%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">259 (211; 307)</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt"> </span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-indent:-8pt; padding-left:8pt"><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">†</span><span style="font-family:Times New Roman; font-size:9pt">Los pacientes que no completaron el tratamiento se consideraron fracasos: los pacientes que interrumpieron de forma prematura el tratamiento se imputan como fracaso a partir de entonces. Se notificaron el porcentaje de pacientes con respuesta y el intervalo de confianza (IC) del 95</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">% correspondiente.</span></p><p style="margin:0pt; text-indent:-8pt; padding-left:8pt"><span style="font-family:Times New Roman; font-size:6pt; vertical-align:super">‡</span><span style="font-family:Times New Roman; font-size:9pt">Para los análisis por factores pronósticos, los fracasos virológicos fueron arrastrados para porcentajes &lt;40</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">copias/ml. Para los cambios medios en CD4 se usó el valor basal arrastrado para los fracasos virológicos.</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:9pt">Raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">mg una vez al día y raltegravir 400</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">mg dos veces al día se administraron con emtricitabina</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">(+)</span><span style="font-family:Times New Roman; font-size:9pt"> </span><span style="font-family:Times New Roman; font-size:9pt">tenofovir disoproxilo fumarato.</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:8pt"> </span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:169.3pt; border:none">
                                        </td>
                                        <td style="width:81.05pt; border:none">
                                        </td>
                                        <td style="width:82.45pt; border:none">
                                        </td>
                                        <td style="width:79.4pt; border:none">
                                        </td>
                                        <td style="width:95.55pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="0749aa24-f5e3-4f20-be13-159c767e106f"><title value="5.2. Propiedades farmacocinéticas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029827" /><display value="Propiedades farmacocinéticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Absorción</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Como se ha demostrado en voluntarios sanos a los que se les han administrado dosis orales únicas de raltegravir en ayunas, raltegravir se absorbe rápidamente, con un</span><span style="font-family:Times New Roman; font-size:11pt">T</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de aproximadamente 3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas después de su administración. El AUC y la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir aumentan de forma proporcional a la dosis en el intervalo de dosis de 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg a 1.600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg. La C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir aumenta de forma proporcional a la dosis en el intervalo de dosis de 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg a 800</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg y aumenta de forma ligeramente menos proporcional a la dosis en el intervalo de dosis de 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg a 1.600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Con la posología de dos veces al día, el estado de equilibrio farmacocinético se alcanza rápidamente, aproximadamente en los 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">días siguientes a la administración. La acumulación según el AUC y la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">es escasa o nula y hay una ligera acumulación según la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">. La biodisponibilidad absoluta de raltegravir no se ha determinado.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día también se absorbe rápidamente con una mediana de T</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">~1,5 a 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas en el estado de ayuno y genera un pico de absorción más definido con una tendencia a una C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">mayor en comparación con raltegravir dos veces al día (1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día). Por otro lado, en comparación con la formulación de raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, la formulación de raltegravir 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg utilizada en la pauta posológica de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (2 x 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) una vez al día presenta una biodisponibilidad relativa más alta (del 21 al 66%). Una vez absorbidas, ambas formulaciones de raltegravir muestran una farmacociné</span><span style="font-family:Times New Roman; font-size:11pt">tica sistémica similar. En los pacientes, tras la administración de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de raltegravir una vez al día, el AUC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">0-24</span><span style="font-family:Times New Roman; font-size:11pt">en el estado de equilibrio fue 53,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">h·μM, la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:11pt">fue 75,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">nM, y la mediana de T</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">fue 1,50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">h.</span></p><p style="margin:0pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día se pu</span><span style="font-family:Times New Roman; font-size:11pt">ede administrar con o sin alimentos. En los estudios fundamentales de eficacia y de seguridad realizados en pacientes infectados con el VIH, raltegravir se administró sin tener en cuenta la ingesta de alimentos. Cuando se administraron múltiples dosis de raltegravir tras una comida moderada en grasas, el AUC de raltegravir no se vio afectado en un grado clínicamente significativo, observándose un aumento del 13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% respecto a la administración en ayunas. La C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">de raltegravir fue 66</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% superior y la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">fue 5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% superior tras una comida moderada en grasas en comparación con la administración en ayunas. La administración de raltegravir tras una comida rica en grasas aumentó el AUC y la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">aproximadamente 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces y aumentó la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">en 4,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces. La administración de raltegravir tras una comida baja en grasas redujo el AUC y la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">en un 46</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y un 52</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%, respectivamente; la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">permaneció básicamente invariable. La ingesta de alimentos parece aumentar la variabilidad farmacocinética respecto al ayuno.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos (2 x 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) se puede administrar con o sin comida. Un estudio del efecto de la comida sobre dosis únicas demostró que la pauta de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día presentaba unos efectos de los alimentos similares o menores a los de la pauta de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día en condiciones de comidas ricas y bajas en grasas. La administración de una comida baja en grasas con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día dio lugar a una disminución del 42% del AUC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">0-últ.</span><span style="font-family:Times New Roman; font-size:11pt">, una disminución del 52% de la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">y una disminución del 16% de la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">. La administración de una comida rica en grasas provocó un aumento del 1,9% del AUC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">0-últ.</span><span style="font-family:Times New Roman; font-size:11pt">, un descenso del 28% de la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">y una disminución del 12% de la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En conjunto, se observó una considerable variabilidad en la farmacocinética de raltegravir. Para la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">observada en BENCHMRK 1 y 2, el coeficiente de variación (CV) para la variabilidad interindividual fue</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">212</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y el CV para la variabilidad intraindividual fue</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">122</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%. Las fuentes de variabilidad pueden ser, entre otras, diferencias en la administración simultánea con alimentos y los medicamentos administrados simultáneamente.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Distribución</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Aproximadamente el 83</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de raltegravir se une a las proteínas plasmáticas humanas en el intervalo de concentraciones de 2 a 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">micromolar</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(µM).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir atravesó fácilmente la placenta en ratas, pero no penetró en el cerebro en una magnitud apreciable.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En dos estudios en pacientes infectados por el VIH</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1 que recibieron raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, raltegravir fue detectado fácilmente en el líquido cefalorraquídeo. En el primer estudio (n=18) la mediana de las concentraciones en el líquido cefalorraquídeo fue del 5,8% (intervalo de 1 a 53,5%) de la correspondiente concentración en plasma. En el segundo estudio (n=16), la mediana de las concentraciones en el líquido cefalorraquídeo fue del 3% (intervalo de 1 a 61%) de la correspondiente concentración en plasma. Estas proporciones de medianas son aproximadamente de 3 a 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces inferiores que la fracción libre de raltegravir en plasma.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Biotransformación y excreción</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La semivida terminal aparente de raltegravir es aproximadamente de 9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas, con una fase alfa de la semivida más corta (aproximadamente 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">hora), que supone la mayor parte del AUC. Tras la administración de una dosis oral de raltegravir marcado radiactivamente, aproximadamente el 51</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis se excretó por las heces y el 32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% por la orina. En las heces sólo estaba presente raltegravir, gran parte del cual es probable que procediera de la hidrólisis de raltegravir-glucurónido secretado en la bilis, como se observó en especies de animales en los estudios preclínicos. En la orina se detectaron dos compuestos, raltegravir y raltegravir-glucurónido, los cuales representaron aproximadamente el 9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% y el 23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la dosis, respectivamente. El principal compuesto en la circulación sanguínea fue raltegravir y representó aproximadamente el 70</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de la radiactividad total; el resto de radiactividad en el plasma estaba en forma de raltegravir-glucurónido. Estudios en los que se utilizaron inhibidores químicos selectivos de isoformas y UDP</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">glucuronosiltransferasas</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(UGT) expresados en el ADNc han demostrado que la UGT1A1 es la principal enzima responsable de la formación de raltegravir-glucurónido. Por lo tanto, los datos indican que el principal mecanismo de aclaramiento de raltegravir en los seres humanos es la glucuronidación mediada por la UGT1A1.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Polimorfismo de la UGT1A1</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En una comparación de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes con genotipo *28/*28 con 27</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes con genotipo natural, la media geométrica proporcional (IC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) del AUC fue 1,41</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,96,</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2,09) y la media geométrica proporcional de la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">fue 1,91</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,43,</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2,55). En pacientes que presentan actividad reducida de la UGT1A1, no se considera necesario ajustar la dosis debido al polimorfismo genético.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Poblaciones especiales</span></span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Según un estudio de comparación de formulación en voluntarios adultos sanos, el comprimido masticable y el granulado para suspensión oral tienen una mayor biodisponibilidad oral en comparación con el comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg. En este estudio, la administración del comprimido masticable con una comida rica en grasa condujo a un promedio de un 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de reducción en el AUC, de un 62</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de disminución en la C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">máx</span><span style="font-family:Times New Roman; font-size:11pt">y de un 188</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% de aumento en la</span><span style="font-family:Times New Roman; font-size:11pt">C</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">12hr</span><span style="font-family:Times New Roman; font-size:11pt">en comparación con la administración en ayunas. La administración del comprimido masticable con una comida rica en grasa no afecta a la farmacocinética de raltegravir de forma clínicamente relevante, por lo que el comprimido masticable se puede administrar sin tener en cuenta la ingesta de alimentos. No se ha estudiado el efecto de los alimentos en la formulación en granulado para suspensión oral.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5 muestra los parámetros farmacocinéticos observados con el comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, con el comprimido masticable y con el granulado para suspensión oral, por peso corporal.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">5</span></strong></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Parámetros Farmacocinéticos de Raltegravir en el ensayo IMPAACT</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">P1066 siguiendo las recomendaciones de Dosis de la Sección</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">4.2 (excluyendo recién nacidos)</span></strong></p><p style="margin:0pt; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><thead><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:14.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:15.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Formulación</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:22.74%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Dosis</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:5.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">N*</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:21.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Media geométrica</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">(%CV</span></em></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">)</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">AUC</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">0-12hr</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">(</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">μ</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">M?h)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:20.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">Media geométrica</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><em><span style="font-family:Times New Roman; font-size:10pt;">(%CV</span></em></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span></strong><strong><em><span style="font-family:Times New Roman; font-size:10pt;">)</span></em></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:10pt;">C</span></strong><strong><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:sub">12hr</span></strong><strong><span style="font-family:Times New Roman; font-size:10pt;">(nM)</span></strong></p></td></tr></thead><tbody><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:14.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">≥25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:15.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Comprimido recubierto con película</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:22.74%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">400</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">mg dos veces al día</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:5.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">18</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:21.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">14,1</span><em><span style="font-family:Times New Roman; font-size:10pt;">(121</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%)</span></em></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:20.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">233 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">157</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:14.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">≥25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:15.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Comprimido masticable</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:22.74%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Posología en funció</span><span style="font-family:Times New Roman; font-size:10pt">n del peso, ver las tablas de posología para el comprimido masticable</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:5.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:21.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">22,1 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">36</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:20.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">113 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">80</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:14.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">De 11 a menos de 25</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:15.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Comprimido masticable</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:22.74%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Posología en función del peso, ver las tablas de posología para el comprimido masticable</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:5.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">13</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:21.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">18,6 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">68</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:20.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">82 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">123</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%)</span></em></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:14.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">De 3 a menos de 20</span><span style="font-family:Times New Roman; font-size:10pt"> </span><span style="font-family:Times New Roman; font-size:10pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:15.6%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Suspensión oral</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:22.74%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">Posología en función del peso, ver la tabla de posología del granulado para suspensión oral</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:5.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">19</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:21.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">24,5 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">43</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom; width:20.5%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">113 (</span><em><span style="font-family:Times New Roman; font-size:10pt;">69</span></em><em><span style="font-family:Times New Roman; font-size:10pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:10pt;">%</span></em><span style="font-family:Times New Roman; font-size:10pt">)</span></p></td></tr><tr><td colspan="6" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:0.5pt; padding-right:0.5pt; vertical-align:bottom"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:10pt">*Número de pacientes para los que hay resultados de farmacocinética intensiva con la dosis final recomendada.</span></p><p style="margin:0pt; text-indent:-8.5pt; padding-left:8.5pt"><span style="font-family:Times New Roman; font-size:6.67pt; vertical-align:super">†</span><span style="font-family:Times New Roman; font-size:10pt">Coeficiente de variación geométrico.</span></p></td></tr></tbody><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:64.65pt; border:none">
                                        </td>
                                        <td style="width:69.1pt; border:none">
                                        </td>
                                        <td style="width:100.7pt; border:none">
                                        </td>
                                        <td style="width:23.4pt; border:none">
                                        </td>
                                        <td style="width:94.25pt; border:none">
                                        </td>
                                        <td style="width:90.8pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes de edad avanzada</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observó un efecto clínicamente significativo de la edad sobre la farmacocinética de raltegravir en el intervalo de edad estudiado con raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día. No se observó un efecto clínicamente significativo de la edad sobre la farmacocinética de raltegravir en el intervalo de edad estudiado en el ensayo ONCEMRK con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">x</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) una vez al día.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Sexo, raza, grupo étnico y peso corporal</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observaron diferencias farmacocinéticas clínicamente importantes en función del sexo, de la raza, del grupo étnico o del peso corporal en adultos en lo que respecta a raltegravir 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, y se llegó a la conclusión de que no existía ningún efecto clínicamente significativo sobre la farmacocinética de raltegravir. En el caso de raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (2 x 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) una vez al día, el análisis farmacocinético poblacional también demostró que la repercusión del sexo, la raza, el grupo étnico y el peso corporal no es clínicamente significativa.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia renal</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La excreción por vía renal del medicamento intacto es una vía poco importante de eliminación. En adultos, no se detectaron diferencias farmacocinéticas clínicamente importantes entre los pacientes que presentaban insuficiencia renal grave y los pacientes sanos (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2 de la ficha técnica de la dosis de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día). Debido a que se desconoce la magnitud con la que se puede dializar raltegravir, el medicamento no se debe administrar antes de una sesión de diálisis. No se han realizado estudios sobre insuficiencia renal con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día. Sin embargo, basado en los resultados obtenidos con los comprimidos de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, no se prevé ningún efecto clínicamente significativo.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia hepática</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir se elimina principalmente por glucuronidación en el hígado. En adultos, no se detectaron diferencias farmacocinéticas clínicamente importantes entre los pacientes que presentaban insuficiencia hepática moderada y los pacientes sanos. El efecto de la insuficiencia hepática grave sobre la farmacocinética de raltegravir no se ha estudiado (ver las secciones</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2 y 4.4 de la ficha técnica de la dosis de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día). No se han realizado e</span><span style="font-family:Times New Roman; font-size:11pt">studios sobre insuficiencia hepática con raltegravir 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día. Sin embargo, basado en los resultados obtenidos con los comprimidos de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos veces al día, no se prevé ningún efecto clínicamente significativo para la insuficiencia hepática leve y moderada.</span></p></div></text></section><section id="f26e7299-5aef-437f-bfa8-3d6ef860dc34"><title value="5.3. Datos preclínicos sobre seguridad" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029834" /><display value="Datos preclínicos sobre seguridad" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se han realizado estudios de toxicología no clínica, incluyendo estudios convencionales de farmacología de seguridad, toxicidad a dosis repetidas, genotoxicidad, toxicidad relacionada con el desarrollo y toxicidad en animales juveniles, con raltegravir en ratones, ratas, perros y conejos. Los efectos a niveles de exposición consideradas superiores a los niveles de exposición clínica no indican riesgos especiales para los humanos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Mutagenicidad</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observaron signos de mutagenicidad ni de genotoxicidad en las pruebas</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">de mutagénesis microbiana (Ames), en los ensayos</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">de elución alcalina de rotura del ADN ni en los estudios</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vitro</span></em><span style="font-family:Times New Roman; font-size:11pt">e</span><em><span style="font-family:Times New Roman; font-size:11pt;">in vivo</span></em><span style="font-family:Times New Roman; font-size:11pt">de aberraciones cromosómicas.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Carcinogenicidad</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 11.7pt 0pt 0pt" ><span style="font-family:Times New Roman; font-size:11pt">Un estudio de carcinogenicidad de raltegravir en ratones no mostró ningún potencial carcinogénico. En los niveles más altos de dosis, 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg/día en hembras y 250</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg/día en machos, la exposición sistémica fue similar a la dosis clínica de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día. En ratas, fueron identificados tumores (carcinoma de células escamosas) de la nariz/nasofaringe a dosis de 300 y 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg/día en hembras y de 300</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg/día en machos. Esta neoplasia se podría producir por una deposición local y/o por la aspiración del fármaco a través de la mucosa de la nariz/nasofaringe durante la dosificación oral por sonda y la subsecuente irritación crónica e inflamación; es probable que sea de importancia limitada para el uso clínico. En el NOAEL (nivel sin efecto adverso observable), la exposición sistémica fue similar a la dosis clínica de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día. Los estudios estándar de genotoxicidad para evaluar la mutagenicidad y la clastogenicidad fueron negativos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Toxicidad relacionada con el desarrollo</span></span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Raltegravir no fue teratógeno en los estudios de toxicidad relacionada con el desarrollo realizados en ratas y conejos. Se observó un ligero aumento de la incidencia de costillas supernumerarias,</span><span style="font-family:Times New Roman; font-size:11pt">una variante en el proceso de desarrollo normal,</span><span style="font-family:Times New Roman; font-size:11pt">en fetos de ratas expuestas a raltegravir con una exposición aproximadamente 4,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces mayor que la exposición que se alcanza en los seres humanos con la dosis humana recomendada (DHR) según el AUC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">0-24</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub"> </span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">hr</span><span style="font-family:Times New Roman; font-size:11pt">. No se observaron efectos sobre el desarrollo con una exposición 3,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">veces mayor que la exposición que se alcanza en los seres humanos con la DHR. En conejos no se observaron resultados similares.</span></p></div></text></section></section><section id="536c7ffa-97a8-40ed-a109-a1f0329b19e2"><title value="6. Datos farmacéuticos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029836" /><display value="Datos farmacéuticos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="48aa7f87-01bd-49b6-b3aa-51f224b4a977"><title value="6.1. Lista de excipientes" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029837" /><display value="Lista de excipientes" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Núcleo del comprimido</span></span></p><ul style="margin:0pt; padding-left:0pt" ><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Celulosa microcristalina</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hipromelosa</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2910</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Estearato de magnesio</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Croscarmelosa sódica</span></li></ul><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Recubrimiento</span></span></p><ul style="margin:0pt; padding-left:0pt" ><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Lactosa monohidratado</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hipromelosa 2910</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Dióxido de titanio</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Triacetina</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; page-break-after:avoid; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Óxido de hierro amarillo</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; padding-left:19.69pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Óxido de hierro negro</span></li></ul><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">El comprimido también puede contener trazas de cera de carnauba.</span></p></div></text></section><section id="41635bd1-1383-4c88-a731-79569c25446f"><title value="6.2. Incompatibilidades" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029838" /><display value="Incompatibilidades" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">No procede.</span></p></div></text></section><section id="48df1961-2136-4cd3-b2a7-5106080cf93c"><title value="6.3. Periodo de validez" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029839" /><display value="Periodo de validez" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años</span></p></div></text></section><section id="23a8ad0d-fceb-474f-a0be-5b3ce0c5d448"><title value="6.4. Precauciones especiales de conservación" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029840" /><display value="Precauciones especiales de conservación" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Mantener el frasco perfectamente cerrado, con el desecante para protegerlo de la humedad.</span></p></div></text></section><section id="bf62e8e6-8b2a-4645-bb69-5acfc49662d5"><title value="6.5. Naturaleza y contenido del envase" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029841" /><display value="Naturaleza y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Frasco de polietileno de alta densidad (HDPE) con cierre de seguridad de polipropileno a prueba de niños, sellado por inducción y desecante de gel de sílice.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Hay disponibles dos tamaños de envases: 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">frasco de 60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos y un envase múltiple conteniendo 180 (3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">frascos de 60) comprimidos.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente estén comercializados algunos tamaños de envases.</span></p></div></text></section><section id="7df9d29b-b8aa-4cb2-a6e2-f745fd04886e"><title value="6.6. Precauciones especiales de eliminación y otras manipulaciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029842" /><display value="Precauciones especiales de eliminación y otras manipulaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Ninguna especial para su eliminación.</span></p></div></text></section></section><section id="2ddc47e1-a89a-4024-98eb-381bc8b8043c"><title value="7. Titular de la autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029844" /><display value="Titular de la autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme B.V.</span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Waarderweg 39</span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">2031 BN Haarlem</span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Países Bajos</span></p></div></text></section><section id="6dab8d18-6c15-4167-81e6-a878a99569d7"><title value="8. Número(s) de autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029845" /><display value="Número(s) de autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-indent:-28.35pt; page-break-after:avoid; padding-left:28.35pt" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/07/436/006</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/07/436/007</span></p></div></text></section><section id="7cfb0345-1cdb-4248-ad0f-508f9fcebe39"><title value="9. Fecha de la primera autorización/ renovación de la autorización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029846" /><display value="Fecha de la primera autorización/ renovación de la autorización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-indent:-28.35pt; page-break-after:avoid; padding-left:28.35pt" ><span style="font-family:Times New Roman; font-size:11pt">Fecha de la primera</span><span style="font-family:Times New Roman; font-size:11pt">autorización</span><span style="font-family:Times New Roman; font-size:11pt">: 20/diciembre/2007</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Fecha de la última renovación: 14/mayo/2014</span></p></div></text></section><section id="b66a913f-0b5e-431f-9428-8acace21a879"><title value="10. Fecha de la revisión del texto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029847" /><display value="Fecha de la revisión del texto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos</span><a href="http://www.ema.europa.eu"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; color:#0000ff">http://www.ema.europa.eu</span></span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p></div></text></section></section></Composition></resource></entry></Bundle></resource></entry><entry><fullUrl value="64e3cdd1-cab9-4e92-9215-3a5937946726" /><resource><Bundle><id value="64e3cdd1-cab9-4e92-9215-3a5937946726" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="64e3cdd1-cab9-4e92-9215-3a5937946726" /></identifier><type value="document" /><timestamp value="2024-12-04T17:54:32.9550059+01:00" /><entry><fullUrl value="64e3cdd1-cab9-4e92-9215-3a5937946726" /><resource><Composition><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="100000155538" /><display value="Prospecto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2024-12-04" /><author><reference value="systemUser" /></author><title value="Prospecto" /><section><title value="Prospecto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="200000029894" /><display value="Prospecto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><h5 style="margin:0pt 0pt 10pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt; font-weight:normal"><span style="font-family:Times New Roman; font-size:11pt"> </span></h5><h5 style="margin:0pt 0pt 10pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt; font-weight:normal"><strong><span style="font-family:Times New Roman; font-size:11pt; text-decoration:none">Prospecto: información para el usuario</span></strong></h5><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Isentress 600</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg comprimidos recubiertos con película</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">raltegravir</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene información importante para usted.</span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si usted es el padre de un niño que toma Isentress, por favor lea atentamente esta información con su hijo.</span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conserve este prospecto, ya que puede tener que volver a leerlo.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene alguna duda, consulte a su médico, farmacéutico o enfermero.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento se le ha recetado solamente a usted o a su hijo, y no debe dárselo a otras personas aunque tengan los mismos síntomas que usted, ya que puede perjudicarles.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si experimenta efectos adversos, consulte a su médico, farmacéutico o enfermero, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Contenido del prospecto</span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">1.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Qué es Isentress y para qué se utiliza</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">2.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Qué necesita saber antes de empezar a tomar Isentress</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">3.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Cómo tomar Isentress</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">4.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Posibles efectos adversos</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">5.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Conservación de Isentress</span></p><p style="margin:0pt; text-indent:-28.35pt; line-height:115%; padding-left:28.35pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">6.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">Contenido del envase e información adicional</span></p></div></text><section id="e129cff0-abc8-4be0-ae4e-fb41e522a3c6"><title value="1. Qué es Isentress y para qué se utiliza" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029895" /><display value="Qué es &quot;X&quot; y para qué se utiliza" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Qué es Isentress</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Isentress contiene el principio activo raltegravir. Isentress es un medicamento antiviral que actúa frente al virus de la inmunodeficiencia humana (VIH). Este es el virus que causa el síndrome de inmunodeficiencia adquirida (SIDA).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cómo actúa Isentress</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El virus produce una enzima llamada integrasa del VIH, la cual ayuda al virus a entrar en las células del organismo y a multiplicarse. Isentress impide que esta enzima realice su función. Cuando se utiliza con otros medicamentos, Isentress puede reducir la cantidad de VIH en sangre (esto se denomina su “carga viral”) e incrementar el recuento de células</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">CD4 (un tipo de glóbulos blancos que tienen un papel importante manteniendo el sistema inmunitario sano para ayudar a combatir la infección). Al reducir la cantidad de VIH en la sangre, puede mejorar el funcionamiento de su sistema inmunitario. Esto significa que su cuerpo puede luchar mejor contra la infección.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Cuando se debe utilizar Isentress</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Isentress 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg comprimidos recubiertos con película se utiliza para tratar a adultos y pacientes pediátricos con un peso de al menos 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg que están infectados con el VIH. Su médico le ha prescrito Isentress para que le ayude a controlar la infección por el VIH que padece.</span></p></div></text></section><section id="a26ba653-31a4-4c64-9bab-5afeb08a2d63"><title value="2. Qué necesita saber antes de empezar a &lt;tomar&gt;&lt;usar&gt; Qué necesita saber antes de empezar a tomar Isentress" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029896" /><display value="Qué necesita saber antes de empezar a &lt;tomar&gt;&lt;usar&gt; &quot;X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="00adecbb-bff7-4bb1-9266-0989f0f70295"><title value="No tome Isentress:" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029897" /><display value="No tome Isentress:" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">si es alérgico a raltegravir o a alguno de los demás componentes de este medicamento (incluidos en la sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6).</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="65daf1a5-254e-4341-b455-45db406b2c98"><title value="Advertencias y precauciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029898" /><display value="Advertencias y precauciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Consulte a su médico, farmacéutico o enfermero antes de empezar a tomar Isentress.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Recuerde que Isentress no cura la infección por el VIH. Esto significa que puede seguir presentando infecciones u otras enfermedades relacionadas con el VIH. Debe seguir acudiendo a la consulta del médico regularmente mientras toma este medicamento.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Problemas de salud mental</span></span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico si tiene antecedentes de depresión o enfermedad mental. Se ha observado depresión, incluyendo pensamientos y conductas suicidas en algunos pacientes mientras tomaban este medicamento, especialmente en pacientes con antecedentes previos de depresión o enfermedad mental.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Problemas óseos</span></span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Algunos pacientes que sigan un tratamiento antirretroviral de combinación pueden desarrollar una enfermedad ósea denominada osteonecrosis (muerte del tejido óseo causada por la pérdida de irrigación sanguínea al hueso). La duración del tratamiento antirretroviral de combinación, el uso de corticosteroides, el consumo de alcohol, la reducción grave de la actividad del sistema inmunológico, el aumento del índice de masa corporal, entre otros, pueden ser algunos de los muchos factores de riesgo para desarrollar esta enfermedad. Los signos de osteonecrosis son rigidez articular, molestias y dolor (especialmente en la cadera, rodilla y hombro) y dificultad de movimiento. Si sufre cualquiera de estos síntomas, acuda a su médico.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Problemas hepáticos</span></span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico, farmacéutico o enfermero si ha tenido problemas con su hígado con anterioridad, incluidas la hepatitis</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">B o C. Su médico puede evaluar la gravedad de su enfermedad hepática antes de decidir si puede tomar este medicamento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Infecciones</span></span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si nota algún síntoma de infección, tales como fiebre y/o se encuentra mal, comuníqueselo a su médico, farmacéutico o enfermero inmediatamente. Algunos pacientes con infección por el VIH avanzada y que han sufrido anteriormente infecciones oportunistas pueden presentar signos y síntomas de inflamación a causa de las infecciones anteriores poco después de empezar el tratamiento contra el VIH. Se cree que estos síntomas se deben a la mejora de la respuesta inmunitaria del organismo, que permite al organismo luchar contra infecciones que es posible que ya tuviera pero que no producían síntomas obvios.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Además de las infecciones oportunistas, también pueden aparecer trastornos autoinmunitarios (una afección que ocurre cuando el sistema inmunitario ataca tejido corporal sano) después de que usted haya empezado a tomar medicamentos para el tratamiento de su infección por VIH. Los trastornos autoinmunitarios pueden aparecer muchos meses después del inicio del tratamiento. Si observa cualquier síntoma de infección u otros síntomas como por ejemplo debilidad muscular, debilidad que empieza en las manos y pies y que asciende hacia el tronco del cuerpo, palpitaciones, temblor o hiperactividad, informe a su médico inmediatamente para recibir el tratamiento necesario.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Problemas musculares</span></span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Contacte inmediatamente con su médico, farmacéutico o enfermero si nota dolor muscular inexplicado, sensibilidad a la presión o debilidad muscular durante el tratamiento con este medicamento.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Problemas de la piel</span></span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Contacte inmediatamente con su médico si presenta una erupción. Se han comunicado reacciones cutáneas graves y potencialmente mortales y reacciones alérgicas en algunos pacientes que toman este medicamento.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Otros medicamentos e Isentress</span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico, farmacéutico o enfermero si está tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Isentress puede interactuar con otros medicamentos. Informe a su médico, farmacéutico o enfermero si está tomando, ha tomado recientemente o pudiera tener que tomar:</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">antiácidos (un medicamento que contrarresta o neutraliza el ácido del estómago y alivia la indigestión y el ardor de estómago)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sales de hierro (para tratar y prevenir la deficiencia de hierro o la anemia). Debe esperar al menos dos</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">horas entre la toma de sales de hierro y la toma de Isentress, ya que estos medicamentos pueden reducir la eficacia de Isentress.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">atazanavir (un medicamento antirretroviral)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">rifampicina (un medicamento utilizado para tratar algunas infecciones como la tuberculosis)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">tipranavir/ritonavir (medicamentos antirretrovirales)</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Lleve consigo una lista de todos sus medicamentos para mostrársela a su médico y farmacéutico.</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puede pedirle a su médico o farmacéutico que le dé una lista de los medicamentos que interactúan con Isentress.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No empiece a tomar un medicamento nuevo sin avisar a su médico. Su médico puede decirle si es seguro tomar Isentress con otros medicamentos.</span></li></ul><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="5f0538c6-1210-410a-a5a1-d669183db5ba"><title value="Toma de Isentress con alimentos y bebidas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029901" /><display value="Toma de Isentress con alimentos y bebidas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-indent:-36pt; line-height:115%; padding-left:36pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3.</span></p><p style="margin:0pt; text-indent:-36pt; line-height:115%; padding-left:36pt; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="c3165bc1-90d8-49b0-ad10-f0cb1edd81b5"><title value="Embarazo y lactancia" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029902" /><display value="Embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si está embarazada o en periodo de lactancia, cree que podría estar embarazada o tiene intención de quedarse embarazada, consulte a su médico o farmacéutico antes de utilizar este medicamento.</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Isentress 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (dos comprimidos de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una vez al día) no está recomendado en el embarazo, porque no se ha estudiado en mujeres embarazadas.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se recomienda que las mujeres que conviven con el VIH den el pecho porque la infección por VIH puede transmitirse al bebé a través de la leche materna.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si está dando el pecho o piensa en dar el pecho, debe consultar con su médico lo antes posible.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si está embarazada o en período de lactancia, consulte a su médico, farmacéutico o enfermero antes de utilizar cualquier medicamento.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="9361926a-e82b-4a8e-89f0-1c6942c24438"><title value="Conducción y uso de máquinas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029903" /><display value="Conducción y uso de máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No maneje máquinas, conduzca ni monte en bicicleta si se siente mareado después de tomar este medicamento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Isentress contiene lactosa</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene lactosa. Si su médico le ha indicado que padece una intolerancia a ciertos azúcares, consulte con él antes de tomar este medicamento.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Isentress contiene sodio</span></strong></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene menos de 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mmol de sodio (23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) por comprimido; esto es, esencialmente “exento de sodio”.</span></p></div></text></section></section><section id="988c7f57-3a8a-4462-a649-192fa7447274"><title value="3. Cómo tomar Isentress" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029905" /><display value="Cómo &quot;&lt;tomar&gt;&lt;usar&gt; X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Siga exactamente las instrucciones de administración de este medicamento indicadas por su médico, farmacéutico o enfermero. En caso de duda, consulte de nuevo a su médico, farmacéutico o enfermero. Isentress se debe usar en combinación con otros medicamentos para la infección por el VIH.</span></p><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Qué cantidad</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">se debe</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">tomar</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adultos,</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">niños y adolescentes que pesen al menos 40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">kg</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada es de 1.200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg tomada como dos comprimidos de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por vía oral una vez al día.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No masticar, machacar o partir los comprimidos porque puede modificar la cantidad de medicamento dentro de su cuerpo. Puede tomar este medicamento con o sin alimentos o bebidas.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Isentress además está disponible en comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, en comprimido masticable y en granulado para suspensión oral.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No intercambiar entre el comprimido de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, el comprimido de 400</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, el comprimido masticable o el granulado para suspensión oral sin consultar primero con su médico, farmacéutico o enfermero.</span></p></div></text><section id="597ad492-adc4-4054-a33b-1aad66d1bb1c"><title value="Si toma más Isentress del que debe" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029907" /><display value="Si toma más Isentress del que debe" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No tome más comprimidos de los que le ha recomendado el médico. Si toma más comprimidos de los recomendados, consulte a su médico.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="8cb2fd30-191c-4523-a7b4-84c1e7348fd8"><title value="Si olvidó tomar Isentress" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029908" /><display value="Si olvidó tomar Isentress" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si olvida tomar una dosis, tómela tan pronto como se acuerde de que no la ha tomado.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No obstante, si es hora de tomar la dosis siguiente, no tome la dosis olvidada y siga su pauta posológica habitual.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No tome una dosis doble para compensar las dosis olvidadas.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="b6e314e4-d835-4961-93db-67de16cfecb1"><title value="Si interrumpe el tratamiento con Isentress" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029909" /><display value="Si interrumpe el tratamiento con Isentress" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante que tome Isentress exactamente tal como se lo ha dicho su médico.</span><span style="font-family:Times New Roman; font-size:11pt">No cambie la dosis ni deje de tomar este medicamento sin consultar primero con su médico, farmacéutico o enfermero.</span><span style="font-family:Times New Roman; font-size:11pt">No deje de tomarlo, porque:</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es muy importante que tome todos los medicamentos para el VIH tal como se los han prescrito y en las horas del día correctas. Esto hace que los medicamentos funcionen mejor y también reduce la posibilidad de que dejen de ser capaces de combatir el VIH (a esto se le llama también “resistencia a fármacos”).</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Cuando le queden pocos comprimidos de Isentress, vaya al médico o a la farmacia para obtener más. El motivo es que es muy importante no quedarse sin medicina, ni siquiera durante unos días. Si deja de tomar el medicamento durante unos días, puede que la cantidad de virus en la sangre aumente y, como consecuencia, que el VIH desarrolle resistencia a Isentress y la enfermedad sea más difícil de tratar.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su médico, farmacéutico o enfermero.</span></p></div></text></section></section><section id="c1233235-f0b2-4ad1-b399-9043e6fce525"><title value="4. Posibles efectos adversos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029910" /><display value="Posibles efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Efectos adversos graves</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">–</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">estos son poco frecuentes (pueden afectar hasta 1 de cada 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">personas)</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Acuda al médico inmediatamente si observa cualquiera de los siguientes efectos adversos:</span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones por herpes incluido herpes zoster</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">anemia incluida la producida por deficiencia de hierro</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">signos y síntomas de infección o inflamación</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">trastorno mental</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">intento o intención de suicidio</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación de estómago</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación de hígado</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">fallo hepático</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">erupción de tipo alérgico</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">determinados tipos de problemas del riñón</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ingestión del medicamento en cantidades superiores a las recomendadas</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Acuda a su médico inmediatamente si observa cualquiera de los efectos adversos citados anteriormente.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes:</span><span style="font-family:Times New Roman; font-size:11pt">los siguientes efectos adversos pueden afectar hasta 1 de cada 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">personas</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">disminución del apetito</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">problemas para dormir; sueños extraños; pesadillas; comportamiento anormal; sensación de tristeza profunda y falta de autoestima</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">mareos; dolor de cabeza</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">vértigo</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">flatulencia o gases; dolor abdominal; diarrea; cantidad excesiva de gas en el estómago o en el intestino; náuseas; vómitos; indigestión; eructos</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">determinados tipos de erupción (con mayor frecuencia cuando se usa en combinación con darunavir)</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cansancio, cansancio o debilidad inusuales; fiebre</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">valores elevados de los parámetros hepáticos; valores anormales de leucocitos; aumento de los niveles de grasa en sangre; aumento de los niveles de enzimas de las glándulas salivares o del páncreas</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes: los siguientes efectos adversos pueden afectar hasta 1 de cada 100</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">personas</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infección de las raíces del cabello; gripe; infección de la piel debido a virus; vómitos o diarrea debido a un agente infeccioso; infección del tracto respiratorio superior; acumulación de pus en ganglio linfático</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">verrugas</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor en ganglios linfáticos; recuento bajo de los leucocitos responsables de combatir las infecciones; hinchazón de las glándulas del cuello, axilas e ingles</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reacción alérgica</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento del apetito; diabetes; elevación del colesterol y lípidos de la sangre; aumento de los niveles de azúcar en la sangre; sed excesiva; pérdida de peso severa; altos niveles de grasa en sangre (tales como colesterol y triglicéridos); trastornos de la grasa corporal</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sensación de angustia; sensación de confusión; estado de ánimo deprimido; cambios en el estado de ánimo; ataque de pánico</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">pérdida de memoria; dolor en la mano debido a compresión nerviosa; alteración de la atención; mareo al cambiar de postura de forma rápida; gusto anormal; aumento de la somnolencia; falta de energía; olvidos; cefalea migrañosa; pérdida de sensibilidad, adormecimiento o debilidad de los brazos y/o piernas; hormigueo; somnolencia; dolor de cabeza por tensión; temblores; sueño deficiente</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alteración de la visión</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">zumbidos, sonidos agudos, silbidos, pitidos u otros ruidos persistentes en los oídos</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">palpitaciones; pulsaciones lentas; latidos cardíacos rápidos o irregulares</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sofocos; aumento de la presión arterial</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">voz ruda, áspera o forzada; hemorragia nasal; congestión nasal</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor abdominal superior; molestia rectal; estreñimiento; sequedad de boca; ardor de estómago; dolor al tragar; inflamación del páncreas; úlcera o herida en el estómago o en el intestino superior; sangrado en el ano; malestar de estómago; inflamación de las encías; hinchazón, lengua enrojecida y ulcerada</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">acumulación de grasa en el hígado</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">acné; pérdida o adelgazamiento del cabello; enrojecimiento de la piel; distribución inusual de grasa en el cuerpo, esto puede incluir pérdida de grasa en piernas, brazos y cara e incremento de grasa en el abdomen; sudoración excesiva; sudores nocturnos; engrosamiento y picor de la piel debido a rascado repetido; lesión cutánea; sequedad de la piel</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de las articulaciones; enfermedad articular dolorosa; dolor de espalda; dolor en huesos/músculos; dolorimiento o debilidad muscular; dolor de cuello; dolor en los brazos o las piernas; inflamación de los tendones; disminución de la cantidad de minerales en el hueso</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">piedras en el riñón; micción nocturna; quiste renal</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">disfunción eréctil; agrandamiento de las mamas en hombres; síntomas menopáusicos</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">molestias en el pecho; escalofríos; hinchazón de la cara; sensación de nerviosismo; sensación de malestar generalizado; bulto en el cuello; hinchazón de manos, tobillos o pies; dolor</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">número bajo de glóbulos blancos; número bajo de plaquetas en sangre (un tipo de célula que interviene en la coagulación de la sangre); disminución de la función renal en el análisis de sangre; niveles altos de azúcar en sangre; enzimas musculares elevadas en la sangre; azúcar en la orina; glóbulos rojos en la orina; aumento de peso; aumento del perímetro de la cintura; disminución de proteínas de la sangre (albúmina); aumento del tiempo de coagulación de la sangre</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Otros efectos adversos en niños y adolescentes</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hiperactividad</span></li></ul></div></text><section id="77623c45-5876-442e-a806-aff43fe1e991"><title value="Comunicación de efectos adversos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029912" /><display value="Comunicación de efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text></section><section id="2c767225-24d8-437e-8c92-06fe35a7e656"><title value="Si experimenta cualquier tipo de efecto adverso, consulte a su médico, farmacéutico o enfermero, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto.También puede comunicarlos directamente a través delsistema nacional de notificación incluido en elApéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento." /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="Si experimenta cualquier tipo de efecto adverso, consulte a su médico, farmacéutico o enfermero, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto.También puede comunicarlos directamente a través delsistema nacional de notificación incluido en elApéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento." /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text></section></section><section id="76ef6f77-a0fa-491c-b6ab-65629be5bdee"><title value="5. Conservación de Isentress" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029913" /><display value="Conservación de &quot;X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mantener este medicamento fuera de la vista y del alcance de los niños.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No utilice este medicamento después de la fecha de caducidad que aparece en el frasco después de CAD. La fecha de caducidad es el último día del mes que se indica.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; line-height:13pt; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mantener el frasco perfectamente cerrado, con el desecante (agente secante) para protegerlo de la humedad. No tragar el desecante.</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="123fc1f4-9618-4e5b-b7dd-bf3cfaabe9df"><title value="6. Contenido del envase e información adicional" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029914" /><display value="Contenido del envase e información adicional" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="8a59f40a-eb6a-4efa-9c46-bd7308826397"><title value="Composición de Isentress" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029915" /><display value="Composición de Isentress" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El principio activo es raltegravir. Cada comprimido recubierto con película contiene 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de raltegravir (potásico).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los demás componentes son: celulosa microcristalina, hipromelosa</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2910, croscarmelosa sódica y estearato de magnesio. Además, el recubrimiento contiene los siguientes componentes inactivos: lactosa monohidrato, hipromelosa</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2910, dióxido de titanio, triacetina, óxido de hierro amarillo y óxido de hierro negro. El comprimido también puede contener trazas de cera de carnauba.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="83d27c11-6be3-4f0d-9400-cf34fd0bdf83"><title value="Aspecto del producto y contenido del envase" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029916" /><display value="Aspecto del producto y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El comprimido de 600</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg recubierto con película es de forma ovalada, de color amarillo, con el logo corporativo MSD y la inscripción “242” grabada en una de las caras y la otra cara lisa.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hay disponibles dos tamaños de envases</span><span style="font-family:Times New Roman; font-size:11pt">: envases de 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">frasco de 60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos y envases múltiples conteniendo 3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">frascos de 60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">comprimidos cada uno. El frasco contiene desecante.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente estén comercializados algunos tamaños de envases.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="64e94110-8139-4833-b742-7b3a2e7e0bd2"><title value="Titular de la autorización de comercialización y responsable de la fabricación" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029917" /><display value="Titular de la autorización de comercialización y responsable de la fabricación" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme B.V.</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Waarderweg 39</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">2031 BN Haarlem</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Países Bajos</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Pueden solicitar más información respecto a este medicamento dirigiéndose al representante local del titular de la autorización de comercialización:</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%"><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">België/Belgique/Belgien</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Belgium</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tél/Tel: +32(0)27766211</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dpoc_belux@msd.com</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lietuva</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">UAB Merck Sharp &amp; Dohme</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+370</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">278</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">02</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">47</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msd_lietuva@merck.com</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="258" height="69" alt="" /></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Luxembourg/Luxemburg</span></strong></p><p style="margin:0pt; line-height:13pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Belgium</span></p><p style="margin:0pt; line-height:13pt"><span style="font-family:Times New Roman; font-size:11pt">Tél/Tel: +32(0)27766211</span></p><p style="margin:0pt; line-height:13pt"><span style="font-family:Times New Roman; font-size:11pt">dpoc_belux@ms</span><span style="font-family:Times New Roman; font-size:11pt">d.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ceská republika</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme</span><span style="font-family:Times New Roman; font-size:11pt">s.r.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+420</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">233</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">010</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">111</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dpoc_czechslovak@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Magyarország</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Pharma Hungary Kft.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+36 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">888</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">53</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">00</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hungary_msd@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Danmark</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Danmark ApS</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: +45 4482 4000</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dkmail@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Malta</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merc</span><span style="font-family:Times New Roman; font-size:11pt">k Sharp &amp; Dohme Cyprus Limited</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8007 4433 (+356 99917558)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">malta_info@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Deutschland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Sharp &amp; Dohme GmbH</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel:</span><span style="font-family:Times New Roman; font-size:11pt">0800 673 673 673 (</span><span style="font-family:Times New Roman; font-size:11pt">+49 (0) 89 4561 0)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">e-mail</span><span style="font-family:Times New Roman; font-size:11pt">@msd.de</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Nederland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme B.V.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: 0800 9999000 (+31 23 5153153)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">medicalinfo.nl@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Eesti</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme OÜ</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: +372</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6144 200</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msdeesti@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Norge</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD (Norge) AS</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: +47 32 20 73 00</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msdnorge@msd.no</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ελλ?δα</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Α.Φ.Β.Ε.Ε.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Τηλ</span><span style="font-family:Times New Roman; font-size:11pt">: + 30 210 98 97 300</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dpoc_greece@merck.com</span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Österreich</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +43 (0) 1 26 044</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dpoc_austria</span><span style="font-family:Times New Roman; font-size:11pt">@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:57.3pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">España</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme de España, S.A.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +34 91 321 06 00</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msd_info@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Polska</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Pol</span><span style="font-family:Times New Roman; font-size:11pt">ska Sp.z o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">22</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">549</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">51</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">00</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msdpolska@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr style="height:56.1pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">France</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD France</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tél: + 33 (0) 1 80 46 40 40</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Portugal</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme, Lda</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel:</span><span style="font-family:Times New Roman; font-size:11pt">+351 21 4465700</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inform_pt@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:63.7pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hrvatska</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme d.o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 385 1 6611 333</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">croatia_info@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">România</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme Romania S.R.L.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +</span><span style="font-family:Times New Roman; font-size:11pt">40 21 529 29 00</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msdromania@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr style="height:63.7pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ireland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme Ireland (Human Health) Limited</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +353 (0)1 2998700</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">medinfo_ireland@msd.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenija</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">386</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5204201</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msd_slovenia@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:53.7pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ísland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Vistor hf.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Sími: +354 535 7000</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenská republika</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme, s. r. o.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+421</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">58282010</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dpoc_czechslovak@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.7pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Italia</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Italia S.r.l.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: 800 23 99 89 (+39 06 361911)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">medicalinformation.it@msd.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Suomi/Finland</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MSD Finland Oy</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puh/Tel: +358 (0) 9 804 650</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">info@msd.fi</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr style="height:38.1pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Κ?προς</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme Cyprus Limited</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Τηλ:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">800 00 673 (</span><span style="font-family:Times New Roman; font-size:11pt">+357</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">22866700)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cyprus_info@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Sverige</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme (Sweden) AB</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +</span><span style="font-family:Times New Roman; font-size:11pt">46 77 5700488</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">medicinskinfo@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr style="height:38.1pt"><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Latvija</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">SIA Merck Sharp &amp; Dohme Latvija</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+371</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">67364</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">224</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">msd_lv@merck.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:3.5pt; padding-right:3.5pt; vertical-align:top; width:50%"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">United Kingdom</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">(Northern Ireland)</span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Merck Sharp &amp; Dohme Ireland (Human Health) Limited</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +353 (0)1 2998700</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">medinfoNI@msd.com</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr></table><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="875b82b4-9526-4888-9928-39f3cedaf36a"><title value="" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos:</span><a href="http://www.ema.europa.eu"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; color:#0000ff">http://www.ema.europa.eu</span></span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section></section></Composition></resource></entry></Bundle></resource></entry></Bundle>